Building sites become "low-carbon gardens" to create "good scenery" around residents.

Science and Technology Daily reporter Zhang Wei correspondent Wu Qi

On April 20th, on the occasion of the 56th World Earth Day, a construction site in Wuxi City, Jiangsu Province opened its doors to popularize the technological achievements of low-carbon construction for the citizens.

"This is the pier of the bridge, just like the’ leg’ of the bridge. Under our feet is an integrated ladder cage and an outer frame platform used for pier construction. Different from other construction sites, these facade platforms are composed of modularity, just like building blocks, which can be assembled by themselves according to production needs, which reduces the steel loss by 25% compared with traditional scaffolding, which is both environmentally friendly and efficient. " The technician of Zhenghe Avenue Project of China Railway Eighth Bureau, the construction party, said.

"In the past, we were faced with all units in the industry. This time, opening the door to the general public is not only a test of the project construction level, but also enhances the communication between enterprises and society." At the activity site, Yang Zhiqiang was introducing the energy-saving and emission-reduction technologies, green construction techniques and the results of resource recycling applied in the project construction to the surrounding residents who came to visit.

Walking into the construction site, there was no smoke and dust generated by mechanical exhaust, and rows of piers rose from the ground to take shape. The standardized and intelligent construction scene made the visiting residents stop to take pictures. Yang Zhiqiang said: "This is an automatic dust monitoring system, which can be intelligently linked with the enclosure spray device. When the values of PM2.5 and PM10 on site exceed the standard, the system will automatically trigger the spray to let the dust’ fall to the ground’, thus realizing dynamic control." Not only do environmental protection in the enclosure be well implemented, but the project department also upgraded the automatic car washing device at the entrance and exit of the construction site. The sewage after precipitation and filtration can be used for secondary washing of vehicles and sprinkling water on roads to suppress dust. Through recycling, the construction water can be saved by 2000 tons on site every year.

From the construction point of view, it is not an easy task to achieve low carbon. Since entering the site, the Zhenghe Avenue project team of China Railway Eighth Bureau has insisted on integrating the concept of "zero carbon" into the construction details, and introduced a number of environmental protection measures in view of the high energy consumption and high pollution points in traditional construction. Through the linkage of mechanization+intelligence+greening, the project construction has started at full speed.

According to Jiang Yong, the person in charge of the project, the idea of reducing carbon in the project department starts from "replacement" and "reduction". For example, after the construction wastes are classified, hard wastes such as concrete blocks and masonry are broken into construction access roads, steel scraps are recycled into safety guardrails, and wood scraps are processed into temporary facility templates, with a comprehensive utilization rate of over 60%; The temporary facilities on the site are all made of reusable materials, and 70% of the components can be reused after the project. In addition, the introduction of solar outdoor lighting in the living quarters of the construction site can save about 12,000 kWh of electricity every year.

"It’s really not the same as the imagined construction site. I used to worry that the production of construction sites nearby would affect my life. Today, I see that there are so many scientific and environmental protection measures to ensure it, and my heart is much more practical!" Ms. Zhang, a surrounding resident who participated in the event, said with emotion. As a key project in Huishan District, Wuxi City, the construction of the bridge substructure of the project is currently in full swing. Talking about the follow-up construction plan, Jiang Yong said that in the future, the project department will actively apply AI technology to help in resource allocation and further realize the carbon reduction goal of the project construction.

(Photo courtesy of the interviewee)

Announcement of Listed Companies in Shanghai Stock Exchange (December 23rd)

  Tonghua dongbao: THDBH151 tablets were approved for clinical application.

  () On the evening of December 22nd, it was announced that Dongbao Zixing, a wholly-owned subsidiary of the company, had recently obtained the approval notice for clinical trial of THDBH151 tablets issued by National Medical Products Administration Drug Evaluation Center. THDBH151 tablet is a double-target inhibitor of gout. Because of its special advantages in mechanism, it can not only inhibit xanthine oxidase (XO) and reduce uric acid production from the source, but also inhibit the reabsorption of uric acid by renal tubular URAT1 transporter and accelerate uric acid excretion.

  Textile City: The share repurchase ratio reaches 4% of the total share capital.

  () Announcement: As of December 22, the company has repurchased 60.18 million shares of the company by centralized bidding, accounting for 4.11% of the company’s total share capital. The highest price of the repurchase transaction is 4.50 yuan/share, and the lowest price is 4.08 yuan/share, with a total transaction amount of 262 million yuan (excluding transaction costs).

  (): GDR is issued and listed on the Swiss Stock Exchange with conditional approval from the Swiss Stock Exchange Supervision Bureau.

  Huayou Cobalt announced that the company recently obtained the conditional approval from the Swiss Stock Exchange Regulatory Authority on the issuance of global depositary receipts ("GDR") and listing on the Swiss Stock Exchange. The Swiss Stock Exchange Regulatory Authority agreed that the GDR issued by the company should be listed on the Swiss Stock Exchange after meeting the customary conditions.

  The cumulative repurchase ratio of textile city reached 4.11%, costing 262 million yuan.

  Textile City announced that by December 22, 2022, the company had bought back 60.176 million shares of the company by centralized bidding, accounting for 4.11% of the company’s total share capital. The highest price of the repurchase transaction was 4.50 yuan/share, the lowest price was 4.08 yuan/share, and the total transaction amount was 262 million yuan (excluding transaction costs).

  Guang ‘an Aizhong was approved to issue corporate bonds of no more than RMB 1 billion.

  () Announcement. Recently, the company received the Reply on Agreeing to the Registration of Sichuan Guang ‘an Aizhong Co., Ltd. to Publicly Issue Corporate Bonds to Professional Investors issued by the China Securities Regulatory Commission, and agreed to the company’s application for registration of publicly issuing corporate bonds with a total face value of no more than 1 billion yuan to professional investors.

  Huayou Cobalt: The issuance and listing of GDR was conditionally approved by the Supervision Bureau of Swiss Stock Exchange.

  Huayou Cobalt announced on the evening of December 22 that the company recently obtained the conditional approval from the Swiss Stock Exchange Regulatory Authority for the company to issue global depositary receipts (GDR) and list on the Swiss Stock Exchange. The Swiss Stock Exchange Regulatory Authority agreed that the GDR issued by the company would be listed on the Swiss Stock Exchange after meeting the customary conditions.

  New Huangpu: It is planned to plan a non-public offering of shares.

  () Announcement, the company intends to issue shares to no more than 35 specific investors in a non-public manner, and the raised funds are intended to be used for the development and construction of real estate projects, old city reconstruction projects, long-term rental projects, etc. related to the company’s "guarantee of property and people’s livelihood", as well as supplementary liquidity and debt repayment that meet the requirements of the refinancing policy of listed companies. The number of shares to be issued in this non-public offering shall not exceed 30% of the total share capital of the company before this offering, and the final number of shares to be issued shall be subject to the number approved by China Securities Regulatory Commission.

  Hao Jing Bo Rui, the major shareholder of Chenguang New Materials, intends to reduce its holdings by no more than 1.8 million shares.

  () Announcement: Jiangsu Hao Jing Bo Rui Landscaping Engineering Co., Ltd. ("Hao Jing Bo Rui"), a shareholder holding 5.18% of the company’s shares, intends to reduce the number of shares of the company by no more than 0.75% of the total shares of the company, that is, no more than 1.8 million shares.

  ST Jiuyou: Shanghai High Court rejected Han Yue’s appeal and upheld the original judgment.

  () Announcement: The company has received the criminal ruling of Shanghai Higher People’s Court forwarded by Tianjin Shengxin regarding the progress of the relevant case of Han Yue, the original actual controller of the company. The main contents are as follows:

  Shanghai No.1 Intermediate People’s Court tried the case that the first branch of Shanghai People’s Procuratorate accused the defendant Han Yue of committing the crime of fund-raising fraud, and on December 29, 2021, it made a criminal judgment of (2019) No.94 at the beginning of Shanghai 01 sentence. Han Yue, the defendant in the original trial, refused to accept the appeal. After the Shanghai Higher People’s Court accepted the case, it formed a collegial panel according to law. After reading the papers, interrogating the defendant and listening to the opinions of the defenders, it was considered that the facts of the case were clear and decided not to hold a trial. The trial is now over.

  The Shanghai Higher People’s Court confirmed that the fact that the defendant Han Yue committed fund-raising fraud in the original judgment was clear, the evidence was indeed sufficient, the applicable law was correct, the sentencing was appropriate and the trial procedure was legal. The appellant’s reasons for appeal and the defender’s defense opinions are inconsistent with the facts and evidence ascertained, and have no basis in law, so the Shanghai High Court will not accept and adopt them. The Shanghai People’s Procuratorate’s suggestion that the Shanghai High Court reject the appeal and uphold the original judgment is correct and should be supported. Now, according to Article 236, Paragraph 1 (1) of the Criminal Procedure Law of People’s Republic of China (PRC), the ruling is as follows: the appeal is dismissed and the original judgment is upheld. This ruling is final.

  Jiansheng Group holds 50,000 shares by director Jiang Feng.

  () Announced that Jiang Feng, the shareholder, director and senior manager of the company, increased his holding of 50,000 shares of the company through the centralized bidding trading system of Shanghai Stock Exchange on December 22nd, accounting for 0.01% of the company’s total share capital.

  New Huangpu: It is planned to raise funds through non-public offering of shares for projects related to Baojiaolou.

  New Huangpu announced on the evening of December 22nd that the company intends to issue shares to no more than 35 specific investors in a non-public manner, and the funds raised will be used for the development and construction of real estate projects, old city reconstruction projects and long-term rental projects related to the company’s "guarantee of property and people’s livelihood", as well as supplementary liquidity and debt repayment that meet the requirements of the refinancing policy of listed companies.

  The subsidiaries of China Power received a total of 69.99 million yuan of government subsidies.

  () Announcement was issued. From November 8, 2022 to the disclosure date of this announcement, the subsidiaries of the company received a total of 69.99 million yuan of government subsidies related to income (unaudited), accounting for 11.42% of the company’s latest audited net profit attributable to shareholders of listed companies.

  Chunqiu Electronics intends to bring some directors and senior executives to increase capital to Dongguan Yingmai Communication, a holding subsidiary.

  () Announcement: The company plans to increase the capital of Dongguan Yingmai Communication Technology Co., Ltd. ("Dongguan Yingmai"), a holding subsidiary of the company, with its own funds of 23 million yuan and some directors and senior management personnel in cash. After the capital increase is completed, the company’s shareholding in Dongguan Yingmai will change from 59.17% to 64.25%.

  Otway: winning the bid for the project of all-in-one machine for scribing and welding of about 155 million yuan.

  Aotewei announced on the evening of December 22nd that the company won the bid for the "All-in-One Welding Project" of New Energy Technology (Quzhou) Co., Ltd., with a total bid of about 155 million yuan (including tax).

  Wanhua Chemical Company’s MDI plant with an annual output of 400,000 tons has been fully connected.

  () It was announced that Wanhua Chemical (Fujian) Isocyanate Co., Ltd., a holding subsidiary of the company, had an annual output of 400,000 tons of MDI, and qualified products were produced on December 22, 2022, achieving a one-time successful start-up.

  New Huangpu plans to raise funds by non-public offering of shares for real estate projects related to "guaranteeing the property and people’s livelihood".

  New Huangpu announced that in order to actively respond to relevant policies, ensure the company’s long-term sustainable development and optimize the capital structure, the company plans to issue shares privately to no more than 35 specific investors, and the raised funds are intended to be used for the development and construction of real estate projects, old city reconstruction projects and long-term rental projects related to the company’s "guarantee of property and people’s livelihood", as well as supplementary liquidity and debt repayment that meet the requirements of the refinancing policies of listed companies. The number of shares to be issued in this non-public offering shall not exceed 30% of the total share capital of the company before this offering, and the final number of shares to be issued shall be subject to the number approved by China Securities Regulatory Commission.

  Nanhua futures: Nanhua Fund, a wholly-owned subsidiary, completed the registration of industrial and commercial change of capital increase and renewed its business license.

  () Announcement: Nanhua Fund Management Co., Ltd., a wholly-owned subsidiary of the company, recently completed the registration of industrial and commercial change of capital increase and obtained the Business License renewed by Dongyang Municipal Market Supervision Administration. After the change, the registered capital of South China Fund is 250 million yuan.

  Fucheng Group, the controlling shareholder of Fucheng, pledged 42 million shares.

  () Announcement: Fucheng Investment Group Co., Ltd. ("Fucheng Group"), the controlling shareholder of the company, released the pledge of 42 million shares on December 21, 2022, accounting for 14.45% of its shares and 5.13% of the company’s total share capital.

  Wang Qiaobin and Cao Liangliang, directors of Concord Electronics, have not reduced their holdings for more than half of the time.

  () Announcement was issued. As of the disclosure date of the announcement, the time for this shareholding reduction plan has been more than half. Directors Wang Qiaobin and Cao Liangliang have not reduced their shareholding in the company, and this shareholding reduction plan has not yet been implemented.

  Yuguang Gold Lead intends to purchase tail gas and flue gas treatment equipment from Yuguang Group, the controlling shareholder.

  () Announcement, the company intends to purchase equipment from the controlling shareholder Henan Yuguang Gold and Lead Group Co., Ltd. (hereinafter referred to as "Yuguang Group"), specifically to purchase the tail gas denitration equipment, flue gas denitration equipment, tail gas particulate matter treatment equipment, flue gas particulate matter treatment equipment, tail gas advanced treatment equipment, etc. built by the project, so as to ensure the company’s green and environmental protection operation, and the target evaluation value is 27.861 million yuan.

  Wenfeng shares has reduced its shareholding in TF Securities.

  () Announcement: According to the situation of the securities market, the company sold () 122 million shares through the securities trading system of Shanghai Stock Exchange from March 3, 2022 to December 21, 2022, with a turnover of 408 million yuan (including handling fees and stamp duty). After this sale, the company no longer holds TF Securities shares.

  Wenfeng shares has reduced its shareholding in TF Securities.

  Wenfeng shares announced that from March 3, 2022 to December 21, 2022, according to the situation of the securities market, the company sold 122 million shares of TF Securities through the securities trading system of Shanghai Stock Exchange in the form of block trading and centralized bidding, with a turnover of 408 million yuan (including handling fees and stamp duty). After this sale, the company no longer holds TF Securities shares.

  Xu Dong, the major shareholder of Nanwei, intends to reduce his shareholding by no more than 5.99%.

  () Announce that Mr. Xu Dong, the shareholder holding more than 5% of the company’s shares, intends to reduce the number of shares by centralized bidding to no more than 5,849,500 shares, that is, no more than 2% of the company’s total shares; Mr. Xu Dong intends to reduce the number of shares by block trading by no more than 11,699,000 shares, that is, no more than 4% of the company’s total shares.

  Otway added three new core technicians, including Wang Mei.

  Otway announced that according to the strategic development plan, the company comprehensively considered the actual situation of the company’s core technology research and development, and after management research, the core technical personnel are now adjusted. Ms. Wang Mei, Mr. Weiguang Jiang and Mr. Jiang Xiaolong were newly added as the company’s core technicians. The former core technicians, Mr. Hong Xu and Mr. Ming Chengru, were no longer recognized as the company’s core technicians due to the adjustment of their work responsibilities, but they continued to work in the company.

  As of the disclosure date of the announcement, the company’s R&D work was carried out normally, and continued to focus on the construction of R&D system. This adjustment of core technicians will not have a significant adverse impact on the company’s sustainable operation ability, R&D strength and core competitiveness.

  Lexus Software: It is planned to buy back shares of RMB 120 million to RMB 200 million.

  Lexus Software announced on the evening of December 22 that the company plans to buy back shares at a price of 120-200 million yuan for employee stock ownership plan or equity incentive, and the repurchase price does not exceed 16.3 yuan/share.

  Aotewei won the bid of 155 million yuan for a new energy cutting and welding integrated machine project.

  Aotewei announced that the company won the bid for a new energy technology (Quzhou) Co., Ltd. "All-in-one welding project", with a total bid amount of about 155 million yuan. Because the average acceptance period of equipment is about 6-9 months, affected by the specific delivery time and acceptance time of the project, the winning project will have a positive impact on the company’s operating performance in 2023.

  Shanghai Jingxing Investment, the major shareholder of Shapu Aisi, has reduced its holdings of 370,000 shares for more than half of the implementation period.

  () Announcement: As of December 22, 2022, Shanghai Jingxing Industrial Investment Co., Ltd. ("Shanghai Jingxing"), a shareholder holding more than 5% of the company’s shares, announced on September 1, 2022 that the shareholding reduction plan was over half, and Shanghai Jingxing reduced its holdings of 370,000 shares by centralized bidding, accounting for 0.0993% of the company’s total share capital after non-public offering.

  New Huangpu: It is planned to issue shares to no more than 35 specific investors in a non-public manner.

  New Huangpu issued a suggestive announcement on the planned non-public offering of shares.

  On December 22nd, New Huangpu issued a suggestive announcement about the planned non-public offering of shares.

  According to the announcement, in order to actively respond to relevant policies, ensure the company’s long-term sustainable development and optimize the capital structure, the company plans to issue shares to no more than 35 specific investors in a non-public manner, and the funds raised are intended to be used for the development and construction of real estate projects related to the company’s "guaranteeing the delivery of buildings and protecting people’s livelihood", old city renovation projects, long-term rental projects, and supplementary liquidity and debt repayment that meet the requirements of the refinancing policy of listed companies. The number of shares to be issued in this non-public offering shall not exceed 30% of the total share capital of the company before this offering, and the final number of shares to be issued shall be subject to the number approved by China Securities Regulatory Commission.

  According to the announcement, up to now, this non-public offering of shares is still in the initial planning stage, and the specific plan for non-public offering of shares has not yet been determined, and there are still uncertainties in this matter.

  Lexus Software plans to spend 120 million to 200 million yuan to buy back shares, and the repurchase price does not exceed 16.3 yuan/share.

  Lexus software announced that the company intends to buy back shares, which will be used for employee stock ownership plan or equity incentive at an appropriate time in the future. The total amount of repurchase funds is not less than RMB 120 million (inclusive) and not more than RMB 200 million (inclusive); The repurchase price shall not exceed RMB 16.3 per share. The repurchase period is within 12 months from the date when the company’s board of directors deliberated and approved this repurchase plan.

  Lu Zhonggeng, the shareholder of Keli Sensing, has reduced his shareholding by 0.57% for more than half of the time.

  () Announcement was issued. Recently, the company received notices from shareholders Lu Zhonggeng and Huang Zhaoxia. As of December 22, more than half of this reduction time, Lu Zhonggeng reduced his holdings by 1,622,100 shares through centralized bidding, with a reduction ratio of 0.57%; Huang Zhaoxia did not reduce his holdings.

  Yingkou Qiyin, the shareholder of GCL Integration, intends to transfer 5.01% of the company’s shares.

  () Announcement, the company recently received a notice from Yingkou Qiyin Investment Management Co., Ltd. (hereinafter referred to as "Yingkou Qiyin"), the concerted action of the controlling shareholder GCL Group Co., Ltd. (hereinafter referred to as "GCL Group"), and Yingkou Qiyin and Shenzhen Qianhai () Financial Holdings Co., Ltd. (hereinafter referred to as "Qianhai Financial Holdings") signed the Share Transfer Agreement on December 21, 2022, and Yingkou Qiyin intends to

  Xianghe Industrial acquired 6.6% equity of Zhongyuan Lida for 48 million yuan.

  () Announced that General Technology was publicly listed on Beijing Equity Exchange to transfer 6.60% equity of Zhongyuan Lida Railway Track Technology Development Co., Ltd. (hereinafter referred to as "Zhongyuan Lida"), and the company participated in the public delisting of 6.60% equity of Zhongyuan Lida and was confirmed as the final transferee. The Company signed the Property Right Transaction Contract with General Technology, stipulating that the transferor will transfer its 6.60% equity of Zhongyuan Lida (including all the rights and obligations contained in such equity) to the Company at a total price of 48 million yuan.

  This transaction is in line with the company’s development strategy, which is conducive to the company to further expand the track fastener business, optimize the industrial layout, deepen the cooperative relationship with the major customer Zhongyuan Lida, improve the company’s core competitiveness and continuously promote the company’s high-quality development. Zhongyuan Lida is one of the few companies in the industry with core technology and the qualification to produce and supply key parts of high-speed rail fastener system. The company’s participation in Zhongyuan Lida can produce good synergy, and the business development will form the same frequency resonance, giving full play to the advantages of both parties and achieving win-win development, which is in line with the interests of the company’s minority shareholders and investors.

  Xianghe Industry: Transferred 6.6% equity of Zhongyuan Lida to expand track fastener business.

  Xianghe Industrial announced on the evening of December 22 that it planned to acquire 6.6% equity of Zhongyuan Lida Railway Track Technology Development Co., Ltd. held by General Technology for 48 million yuan. Zhongyuan Lida is mainly engaged in the manufacturing integration business of railway fastener systems, and this transaction is conducive to the company’s further expansion of rail fastener business.

  Fuda Alloy continues to promote major asset replacement and issue shares to purchase assets and raise matching funds.

  () Announcement: The Review Committee on Mergers and Acquisitions of Listed Companies of China Securities Regulatory Commission ("China Securities Regulatory Commission") held the 22nd working meeting of the Committee on Mergers and Acquisitions in 2022 on November 30, 2022, and reviewed the company’s major asset replacement and issuance of shares to purchase assets and raise matching funds. According to the results of the meeting, the company’s major asset replacement and issuance of shares to purchase assets and raise matching funds were not approved. On December 13th, 2022, the company received the Decision on Not Approving the Application of Forda Alloy Materials Co., Ltd. for Major Asset Replacement and Issuing Shares to Purchase Assets and Raising Matching Funds issued by China Securities Regulatory Commission.

  In view of the fact that this transaction will help the company to further improve its asset quality and scale, enhance its market competitiveness, enhance its profitability and sustainable development ability, benefit the company’s long-term development and conform to the interests of the company and all shareholders. The board of directors of the company decided to continue to promote this transaction, and the 44th meeting of the sixth board of directors was held on December 22nd, 2022, and relevant proposals were reviewed and approved.

  Fucheng shares: 42 million shares held by Fucheng Group, the controlling shareholder, were released from pledge, accounting for 5.13% of the company’s total share capital.

  China Fortune Link December 22-Fucheng shares announced that recently, the company received a notice from Fucheng Group, the controlling shareholder, that it had repaid part of the loan of Yanjiao Branch of Langfang Bank Co., Ltd. in advance, and some of its shares were released from pledge. The number of shares released this time is 42 million shares, accounting for 5.13% of the company’s total share capital.

  Nanwei shares: Xu Dong, a shareholder holding more than 5% of shares, plans to reduce his holdings by no more than about 17,518,800 shares.

  China Fortune Link December 22-Nanwei shares announced that Xu Dong, a shareholder holding more than 5% of shares, intends to reduce the number of shares by centralized bidding, and at the same time, the number of shares to be reduced by block trading is not more than about 11,699,000 shares, that is, the total reduction is not more than about 17,518,800 shares, which is not more than 5.99% of the company’s total share capital.

  Peng Chaoyang, the fund manager of Honeycomb Fengyuan Bond, resigned.

  Today, Honeycomb Fund Management Co., Ltd. announced the change of fund manager, Honeycomb Fengyuan Bond (Class A 012624; Class C 012625) hired Peng Chaoyang, the fund manager, and Jin Zhijie left.

  From 2006 to 2009, Peng Chaoyang served as the investment position of Zhongbao Kanglian Life Insurance Co., Ltd.; From 2009 to 2012, he served as the investment manager of Guohua Life Insurance Co., Ltd. and from 2012 to 2016, he served as the investment manager of soochow securities Co., Ltd.; From 2016 to 2018, he served as the director of fixed income of Caitong Fund Management Co., Ltd.; From 2018 to January 2022, he served as the investment director of Xiangao (Suzhou) Asset Management Co., Ltd.; Joined the Honeycomb Fund in February 2022 as a senior bond researcher; Since December 22, 2022, he has served as the fund manager of Honeycomb Fengyuan Bond Securities Investment Fund.

  Honeycomb Fengyuan Bonds A and C were established on August 20, 2021. By December 21, 2022, their yields this year were 2.01% and 1.70%, respectively. Since their establishment, their yields were 3.05% and 2.64%, and their accumulated net worth was 1.0304 yuan and 1.0264 yuan respectively.

  Sinopharm Hyundai: The holding subsidiary obtained the registration certificate of cytarabine for injection.

  () On the evening of December 22nd, it was announced that Sinopharm, a holding subsidiary, was bent on obtaining the registration certificate of cytarabine for injection. Cytarabine for injection is an antimetabolic drug, which is mainly suitable for the induction, remission and maintenance treatment of acute non-lymphocytic leukemia in adults and children.

  The modern subsidiary of Sinopharm obtained the drug registration certificate for cytarabine for injection.

  Sinopharm Hyundai announced that Sinopharm, a holding subsidiary of the company, wholeheartedly received the registration certificate of cytarabine for injection approved and issued by National Medical Products Administration. Cytarabine for injection is an antimetabolic drug, which is mainly suitable for the induction, remission and maintenance treatment of acute non-lymphocytic leukemia in adults and children.

  This time, Sinopharm has obtained the drug registration certificate for cytarabine for injection, and as the first product in China that has passed the consistency evaluation, it will further enrich the company’s product layout in the field of anti-tumor and immunomodulator, help to enhance the company’s market competitiveness and bring positive influence to the company’s future development. The registration certificate of the drug will not have a significant impact on the company’s current operating performance.

  Shanghai Nianjin, a shareholder of Fudan Microelectronics, plans to reduce its shareholding by no more than 1.8%.

  Fudan Microelectronics announced that Shanghai Nianjin Enterprise Management Consulting Partnership (Limited Partnership) (hereinafter referred to as "Shanghai Nianjin"), a shareholder of the company, plans to reduce its shares by block trading. The reduction period is 90 consecutive natural days after three trading days from the disclosure date of this announcement, and the number of shares reduced does not exceed 14,677,800, accounting for 1.80% of the company’s total share capital.

  Shanghai Xiba subsidiary Gongcheng Environment terminated the transfer of 100% shares of Bodu Technology.

  () Announcement: Shanghai Xiba Gongcheng Environment Co., Ltd., a wholly-owned holding company of the company, and Beijing Jiuting Chenghuan Technology Development Co., Ltd. had previously signed the Share Transfer Cooperation Agreement on December 9, 2021, stipulating that Gongcheng Environment would transfer 100% of its shares in Zhejiang Bodu Technology Co., Ltd. to Jiuting Chenghuan. After the signing of the Share Transfer Cooperation Agreement, both parties set up a condominium account in time, but the relevant transaction plan has never been clearly supported by the land supervision department, and due to the comprehensive influence of other factors, the main contents under the agreement have not yet been fulfilled.

  On December 21, 2022, after careful consultation between Gongcheng Environment and Jiuting City Ring, it was decided to terminate the Equity Transfer Cooperation Agreement signed in the previous period by means of the Agreement.

  Jingneng Power: The 100,000 kW wind power project in hua county was approved.

  () Announcement: Recently, Henan Jingneng Huazhou Thermal Power Co., Ltd., a wholly-owned subsidiary of the company, received the "Reply on the Approval of Jingneng hua county 100,000 kW Wind Power Project" issued by Huaxian Development and Reform Commission; The main information is hereby announced as follows:

  1. In order to make full use of wind energy resources, improve the energy structure, increase the proportion of clean energy and promote economic and social development, we agree in principle to the 100,000 kW wind power project of Jingneng hua county. 2. Project Construction Location: Banpodian, Niutun, Wagangzhai and Jiaohu Town, hua county. III. Project Construction Scale: The total installed capacity of the wind power project is 100 MW. 4. The total investment of the project is 621 million yuan, and the project capital accounts for 20% of the total investment, that is, 124 million yuan, and the rest is solved by bank loans.

  Tony Electronics: Tony Semiconductor, a subsidiary, received a government subsidy of 7,794,100 yuan related to income.

  China Fortune announced on December 22-() that on December 22, 2022, Huzhou Dongni Semiconductor Technology Co., Ltd., a subsidiary of the company, received a revenue-related government subsidy of 7,794,100 yuan, accounting for 23.33% of the company’s audited net profit attributable to shareholders of listed companies in 2021.

  Jingneng Power: Jingneng hua county 100,000 kW wind power project was approved.

  On the evening of December 22nd, Jingneng Electric Power announced that its wholly-owned subsidiary, Henan Jingneng Huazhou Thermal Power Co., Ltd., received the reply from the Development and Reform Commission of hua county, and agreed to the 100,000 kW wind power project in Jingneng hua county with a total investment of 621 million yuan.

  Wan Tai Bio has repurchased 1,585,300 shares to complete the repurchase.

  () Announcement was issued. On December 21st, 2022, the company completed the repurchase, and has repurchased 1,585,300 shares through centralized bidding, accounting for 0.1750% of the company’s total share capital. The highest price of the repurchase transaction was 133.00 yuan/share, the lowest price was 112.74 yuan/share, and the average repurchase price was 126.26 yuan/share, which has been paid cumulatively.

  Hu Xiankuan, Chairman of Jiaojian Co., Ltd., reduced his holdings by 1.5 million shares.

  () Announcement: From November 28, 2022 to December 22, 2022, Hu Xiankuan, the chairman of the company, reduced his holdings of 1.5 million shares through centralized bidding.

  Shanghai Xiba: Termination of the transfer of 100% shares of Bodu Technology Company.

  Shanghai Xiba announced on the evening of December 22 that Gongcheng Environment, a wholly-owned holding company of the company, planned to transfer 100% shares of Zhejiang Bodu Technology Co., Ltd. to Jiuting City Ring for 146 million yuan. Because the relevant transaction plan failed to get the clear support of the land supervision department, it was decided to terminate the equity transfer cooperation agreement signed in the early stage through consultation.

  Changjiang Investment intends to expand the business field of employee accommodation with Zhongfu’s newly established company.

  () Announcement: In order to conform to the construction concept of the Yangtze River Delta eco-green integrated development demonstration zone, the company will expand the business field of employee accommodation. It is agreed that the company and Shanghai Zhongfu Residence Enterprise Group Co., Ltd. ("Zhongfu Residence") jointly set up the Yangtze River Delta Rental Housing (Shanghai) Operation Co., Ltd. (tentative name), with a registered capital of 20 million yuan. Changjiang Investment invested 12 million yuan in cash, accounting for 60% of its shares, and Zhongfu Residence invested 8 million yuan in cash, accounting for 40% of its shares.

  Kang Enbei: The total flavonoids extract and oral patch of Abelmoschus manihot flower, a subsidiary, obtained the drug registration certificate.

  () Announcement: Recently, Hangzhou Kangenbei, a wholly-owned subsidiary of the company, received the Pharmaceutical Registration Certificate of total flavonoids extract of Abelmoschus manihot flower and oral patch approved and issued by National Medical Products Administration.

  The main function of the oral patch of total flavonoids from Abelmoschus manihot flower is to clear away heat. It is used for treating mild recurrent oral ulcer caused by heat accumulation of heart and spleen, with symptoms of oral mucosal ulcer, local redness, burning pain and so on. The total flavonoids extract of Abelmoschus manihot flower is the raw material of Abelmoschus manihot flower total flavonoids oral patch.

  Kangenbei subsidiary Abelmoschus manihot flower total flavone extract and oral patch obtained drug registration certificate.

  Kang Enbei made an announcement. Recently, Hangzhou Kang Enbei Pharmaceutical Co., Ltd. (hereinafter referred to as Hangzhou Kang Enbei), a wholly-owned subsidiary of the company, received the Pharmaceutical Registration Certificate of total flavonoids extract from Abelmoschus manihot flower and oral patch approved and issued by National Medical Products Administration (hereinafter referred to as National Medical Products Administration).

  Kang Enbei: The total flavone extract of Abelmoschus manihot flower and oral patch obtained the drug registration certificate.

  Kang Enbei announced on the evening of December 22nd that Hangzhou Kang Enbei, a wholly-owned subsidiary, had received the registration certificate of total flavone extract of Abelmoschus manihot flower and oral patch medicine approved and issued by National Medical Products Administration. The medicine is mainly used for clearing away heat from heart, and can be used for treating mild recurrent oral ulcer caused by heat accumulation of heart and spleen, with symptoms such as oral mucosal ulcer, local redness, burning pain, etc.

  Southern Power Grid Energy Storage: The main project of Guangdong Huizhou Zhongdong Pumped Storage Power Station is scheduled to start construction on December 23rd.

  () Announcement: Guangdong Huizhou Zhongdong Pumped Storage Power Station Project (hereinafter referred to as "Huizhou Zhongdong Project") is invested and constructed by Huizhou Zhongdong Pumped Storage Power Generation Co., Ltd. (70% owned by China Southern Power Grid Peak Regulation and Frequency Modulation Power Generation Co., Ltd., a wholly-owned subsidiary of China Southern Power Grid Energy Storage Co., Ltd., and 30% owned by China Guangdong Nuclear Power Sales Co., Ltd.), and the main project of the project is scheduled to start on December 23, 2022.

  According to the announcement, Huizhou Zhongdong Pumped Storage Power Station is located in Zhongdong Village, Gaotan Town, Huidong County, Huizhou City, with a total installed capacity of 1.2 million kilowatts (3× 400,000 kilowatts). The main construction contents of the project are upper reservoir, lower reservoir, water conveyance and power generation system, switching station, etc., with an estimated investment of 8.373 billion yuan.

  Southern Power Grid Energy Storage: The main project of Guangdong Huizhou Zhongdong Pumped Storage Power Station started construction.

  Southern Power Grid Energy Storage announced on the evening of December 22 that the main project of Guangdong Huizhou Zhongdong Pumped Storage Power Station Project is scheduled to start on December 23. The total installed capacity is 1.2 million kilowatts (3× 400,000 kilowatts), and the estimated investment is 8.373 billion yuan. Huizhou Zhongdong Energy Storage Power Generation Co., Ltd. (70% owned by China Southern Power Grid Peak Regulation and Frequency Modulation Power Generation Co., Ltd. and 30% owned by China Guangdong Nuclear Power Sales Co., Ltd.) is responsible for the construction of this project.

  7,023,400 restricted shares of China UAV will be listed and circulated on December 29th.

  China UAV announced that the number of restricted shares listed and circulated this time totaled 7,023,400 shares, accounting for 1.0405% of the company’s total share capital, involving a total of 283 shareholders, and this part of restricted shares will be listed and circulated on December 29.

  Jianfa Hecheng: Some directors plan to increase their shares of the company by not less than 10 million yuan.

  () On the evening of December 22nd, it was announced that four people, including Huang Hebin, vice chairman and president of the company, planned to increase the company’s shares within six months, with a total increase of not less than 10 million yuan. There is no price range for this increase plan.

  Some directors and senior executives of Jianfa Hecheng plan to increase their shares of the company by not less than 10 million yuan.

  Jianfa Hecheng announced that four people, including Mr. Huang Hebin, Vice Chairman and President, Mr. Liu Zhixun and Mr. Xu Hui, Vice Presidents and Ms. Gao Weilin, Secretary of the Board of Directors, plan to increase their holdings of the company’s shares with their own funds through centralized bidding trading in the Shanghai Stock Exchange system within six months from December 26, 2022, with a total increase of not less than RMB 10 million. There is no price range for this holding plan, and the holding plan will be implemented according to the fluctuation of the company’s stock price and the overall trend of the capital market.

  Chengdu Gas elected Wang Shouhao as the chairman.

  () Announced that the board of directors of the company elected Mr. Wang Shouhao as the chairman of the company, elected him as a member of the strategy committee of the second board of directors of the company, nominated him as a member of the strategy committee and served as the convener of the strategy committee, with the term of office from the date of deliberation and approval by the board of directors to the date of expiration of the term of office of the second board of directors.

  China CNOOC: The subsidiary plans to purchase 40% equity of CNNC Huihai.

  () Announcement: New Energy Company, a wholly-owned subsidiary of the company, plans to purchase 40% equity of CNNC Huihai Wind Power Investment Co., Ltd. (hereinafter referred to as "CNNC Huihai") held by Donghai Company, a wholly-owned subsidiary of CNOOC, the actual controller of the company, with its own funds of 1.518 billion yuan.

  This transaction can effectively promote the company’s business expansion and talent training in the field of new energy, and effectively promote the company’s green and low-carbon transformation and high-quality development. This transaction is expected to have a positive impact on the company’s financial status and operating results.

  Energy-saving wind power plans to build four wind power projects in Hubei and Henan with a total investment of 2.617 billion yuan.

  () Announcement, the company plans to invest in the establishment of China Energy Saving Laifeng Wind Power Generation Co., Ltd. ("Laifeng Wind Power") and China Energy Saving Xianfeng Wind Power Generation Co., Ltd. ("Xianfeng Wind Power"), both with registered capital of RMB 10 million.

  In addition, the company plans to invest in the construction of the 250,000 kW wind energy storage integration (Phase I) project in Xiangzhou, Hubei Province ("Xiangzhou Project", with a total investment of 780 million yuan (including energy storage investment)), the 110MW wind power project in Xindeng, China ("Sudeng Phase II Project", with a total investment of 821 million yuan) and the 50MW wind power project in Tianshui, Qin Zhou ("Tianshui Project", with a total investment of 3. The total investment of the above wind power projects is 2.617 billion yuan.

  It is reported that Xiangzhou project is an integrated wind storage project developed and constructed by the company in Hubei Province, a key area of the Yangtze River Basin, which can further expand the company’s market share in Hubei Province. The development and construction of Su-Deng Phase II project can further expand the company’s market share in Songxian region. Tianshui project will further expand the company’s market share in Gansu after its completion. Songxian project is a key project for the company to carry out industrial assistance in designated counties. After completion, it can further expand the company’s market share in Henan.

  The controlling shareholder of Zhenhua Co., Ltd. has reduced its shareholding by 0.8% for more than half of the time.

  () Announcement was issued. As of the announcement date, Cai Zaihua, the controlling shareholder, has reduced his holding of 4,092,600 shares through centralized bidding, accounting for about 0.8% of the company’s total share capital. The reduction plan has been reduced for more than half of the time, and the reduction plan has not yet been implemented.

  Holding shares in China: winning two projects.

  () On the evening of December 22nd, it was announced that the company won the bid for the expansion of Chengnan Sewage Treatment Plant in Renqiu Economic Development Zone, Hebei Province and the reclaimed water reuse project in the southern district and the expansion of Beixinzhuang Township Sewage Treatment Plant and the reclaimed water reuse project in the northern district, with a total investment of about 91,398,200 yuan. The company led a consortium with China North China Design and Research Institute of Municipal Engineering Co., Ltd. to win the bid for the EPC general contracting project of Hengshui Lake and Small Lake Ecological Restoration Project in Jizhou District of Hengshui City, with a total investment of about 85,944,800 yuan.

  GCL Integration: The concerted action of the controlling shareholder intends to transfer 5.01% of the company’s shares by agreement.

  On December 22, GCL-IC issued a suggestive announcement about the concerted action of the controlling shareholder to transfer part of the shares. According to the announcement, GCL Integrated Technology Co., Ltd. (hereinafter referred to as "the company" or "GCL Integrated") recently received a notice from Yingkou Qiyin Investment Management Co., Ltd. (hereinafter referred to as "Yingkou Qiyin"), Yingkou Qiyin and Shenzhen Qianhai Oriental Venture Capital Holdings Co., Ltd. (hereinafter referred to as "Qianhai Financial Holdings") signed the Share Transfer Agreement on December 21, 2022, and Yingkou Qiyin intends to transfer its 293,000,000 shares of GCL to Qianhai Financial Holdings by agreement transfer, accounting for 5.01% of the total share capital of GCL.

  After the implementation of the measures to stabilize the share price of Weiao shares, Su Qingyan, the controlling shareholder, increased his holdings by 750,000 shares.

  () Announcement: As of the disclosure date of the announcement, the company’s measures to stabilize the stock price have been implemented. Su Qingyan, the controlling shareholder of the company, has increased the holding of 750,000 shares of the company, accounting for 0.19% of the company’s total share capital. The accumulated holding amount is RMB 5,001,100, and the transaction price range is RMB 5.99 to RMB 8.36 per share.

  China Holdings Co., Ltd. jointly won the bid for EPC of Hengshui Lake Small Lake Ecological Restoration Project in Jizhou District, Hengshui City.

  China Holdings announced that the company ("the leader of the consortium") and the consortium of China North China Design and Research Institute of Municipal Engineering Co., Ltd. were confirmed as the winning bidder for the EPC general contracting project of Hengshui Lake Small Lake Ecological Restoration Project in Jizhou District, Hengshui City; The total investment of the project is about 85,944,800 yuan, and the construction period is 330 calendar days. Winning the bid for this project will further accumulate the company’s experience in wetland projects, enhance its competitiveness in the field of wetland business, and consolidate the company’s dominant position in related business fields in Hebei.

  Nanwei shares: Shareholder Xu Dong plans to reduce his shareholding by no more than 5.99%.

  Nanwei announced after hours on December 22nd that Xu Dong, the shareholder holding more than 5% of the shares, plans to reduce his holdings by no more than 17,518,800 shares, which is no more than 5.99% of the company’s shares. The source of the shares to be reduced is the shares obtained before IPO and transferred from the company’s equity distribution capital reserve to share capital, and the reason for the proposed reduction is personal capital demand.

  Baida Group intends to acquire 20% equity of Zhejiang Xingan Shiye Investment Management Company to expand investment channels.

  () Announcement: In order to further expand investment channels, on December 21st, 2022, the company ("the transferee") and Xinchuang Holding Group Co., Ltd. ("Xinchuang" or "the transferor") signed the Equity Transfer Agreement, and it is planned to acquire 20% of Zhejiang Xingan Shiye Investment Management Co., Ltd. ("Xingan Shiye" or "the target company") held by Xinchuang. Xingan Shiye is a private fund manager registered in asset management association of china.

  It is reported that Zhejiang Baida Asset Management Co., Ltd. ("Baida Asset Management Company"), a wholly-owned subsidiary of the company, as a limited partner, subscribed 60 million yuan with its own funds to invest in Hangzhou Yuanjufeng Venture Capital Partnership (Limited Partnership) managed by Xingan Shiye, and subscribed 40 million yuan with its own funds to invest in Hangzhou Zhefeng Hongsheng Venture Capital Partnership (Limited Partnership) managed by Xingan Shiye. As of the disclosure date of the announcement, the Baida Asset Management Company has made substantial contributions to Yuanju.

  Nanshan aluminum plans to transfer 336,000 tons of electrolytic aluminum production capacity index.

  () Announced that in order to adjust and optimize the industrial layout and asset structure, and conform to the development of national industrial policy, the company plans to transfer 336,000 tons of electrolytic aluminum production capacity, and the corresponding electrolytic aluminum production lines are planned to be shut down and dismantled, including 78 160KA prebaked electrolyzers (with an approved capacity of 36,000 tons/year) and 412 300KA prebaked electrolyzers (with an approved capacity of 300,000 tons/year) and some supporting carbon production lines.

  The plan of holding 0.31% shares by Xie Yulong, the specific shareholder of Dongwei Technology, was completed.

  Dongwei Technology announced that by December 22, 2022, Mr. Xie Yulong, a specific shareholder, had accumulated 461,400 shares of the company, accounting for 0.313% of the company’s total share capital, with an increase of 63,072,900 yuan, which exceeded the planned increase of 63 million yuan. This increase plan has been implemented.

  Sino Medical: Coronary balloon products obtained FDA certification (510).

  Sino Medical announced on the evening of December 22nd that the company’s NC ROCKSTAR non-compliant balloon dilation catheter was certified by the US FDA (510(k)). This product is suitable for balloon catheter dilation for patients with atherosclerosis to improve myocardial perfusion and for autologous coronary artery or bypass stenosis.

  Jianghuai Automobile plans to acquire related assets of Anhui Weilai for 1.704 billion yuan.

  () Announced that, based on the long-term strategic cooperative relationship between Jianghuai Automobile and Anhui Weilai, in order to jointly promote the cooperation of new energy automobile manufacturing, the company plans to acquire the project assets (including equipment and tooling assets) related to the construction in progress-equipment installation project held by Weilai Automobile (Anhui) Co., Ltd. (hereinafter referred to as "Anhui Weilai"), with an estimated transaction price of 1.704 billion yuan.

  Kangwei Century: Helicobacter pylori nucleic acid detection kit obtained medical device registration certificate

  Kangwei announced on the evening of December 22nd that the Helicobacter pylori nucleic acid detection kit independently developed and produced by the company recently received the medical device registration certificate issued by National Medical Products Administration. The company’s Helicobacter pylori nucleic acid detection kit (PCR fluorescent probe method) is used for qualitative detection of Helicobacter pylori nucleic acid in human stool samples in vitro and for auxiliary diagnosis of Helicobacter pylori infection.

  Sino medical coronary balloon products obtained FDA certification.

  Sino Medical announced that in August 2022, the company submitted the registration application materials of the company’s NC ROCKSTAR non-compliant balloon dilation catheter to the US Food and Drug Administration ("FDA"). Recently, the company received a notice from the FDA that the company’s NC ROCKSTAR non-compliant balloon dilation catheter was certified by the FDA (510(k)).

  This product is suitable for balloon catheter dilation for patients with atherosclerosis to improve myocardial perfusion and for autologous coronary artery or bypass stenosis. This product is also suitable for balloon stent (bare metal and drug-eluting stent) after delivery.

  Hengshang Investment, the shareholder of Jiacheng International, plans to reduce its shareholding by no more than 2%.

  () Announced that the shareholder of the company, Hengshang Investment, will reduce its shareholding in the company from 15 trading days to 6 months from the date of announcement due to financial reasons of state-owned enterprise business, and the reduction will not exceed 2% of the company’s total share capital, that is, 4.665 million shares.

  Radio and TV Network: The creditor’s right of 94.1826 million yuan held by Radio and TV Small Loan was won by Xi ‘an Hyde Jinxin.

  Radio and Television Network announced that Shaanxi Radio and Television Jinfu Microfinance Co., Ltd. ("Radio and Television Microfinance"), a subsidiary of the company, publicly transferred its creditor’s rights of 94.1826 million yuan, which was successfully bid by Xi ‘an Hyde Jinxin Enterprise Management Consulting Partnership (Limited Partnership) ("Xi ‘an Hyde Jinxin") on Taobao asset bidding network platform on December 21, 2022, and the final transaction price was 94.1826 million yuan.

  Time and Space Technology won the bid for the construction project of 192 million yuan taxi network car service management platform.

  () Announcement, the company recently received the Notice of Winning Bid from Urumqi Chengtou Urban Construction Resources Development Co., Ltd., and determined that the company was the winning bidder for the "Construction Project of Taxi Network Car Service Management Platform of Urumqi Chengtou Urban Construction Resources Development Co., Ltd.", and the winning bid amount was about 192 million yuan.

  Zhengtai Anneng, which is planning to go public, increased its capital and shares, and 8 powerful companies entered the market with 2.23 billion yuan.

  Source: Polaris Solar Photovoltaic Network

  On the evening of December 22nd, () announced that Zhengtai Aneng, the holding subsidiary of the company, planned to increase capital and share to introduce investors, with a total capital increase of 2,229.4 million yuan, of which 171,982,286 yuan was included in the paid-in capital and 205,741,714 yuan was included in the capital reserve. The existing shareholders of Chint Electric and Chint Anneng have given up the preemptive right of this capital increase. After the completion of this capital increase and share expansion, Chint’s shareholding in Chint Anneng will be changed from 67.0119% to 62.3035%, and Chint Anneng will remain a holding subsidiary of Chint.

  According to the announcement, there are 8 investors who have increased their capital and shares this time. All parties have confirmed that the pre-investment valuation of Zhengtai Anneng is RMB 28 billion (the pre-investment valuation does not include the investment amount of the first investors in this round). Zhengtai Anneng plans to increase the registered capital by 171,982,286 yuan and issue 171,982,286 new shares. The specific amount of capital increase of each party is as follows:

  Note: The total figures in the table are directly added with the detailed figures, and if there is any difference in mantissa, it is due to rounding.

  Zhengtai Electric said that Zhengtai Anneng is mainly engaged in household photovoltaic energy operation and service business. This capital increase and share expansion is conducive to optimizing the governance structure of Zhengtai Anneng, further enhancing its endogenous power and comprehensive competitiveness, increasing the continuous investment in its main business, providing financial support for the rapid and high-quality development of the company’s household photovoltaic business, improving the asset structure and financial situation of Zhengtai Anneng, in line with the company’s long-term development strategy, and helping to further enhance the company’s core competitive advantage.

  In October this year, Chint announced that it planned to spin off the listing of Chint Anneng, and authorized the company and the management of Chint Anneng to start the preparatory work for the spin-off of Chint Anneng. By the end of September this year, the scale of household photovoltaic power stations in Zhengtai Anneng has exceeded 9GW, distributed in 18 provinces, autonomous regions and municipalities such as Anhui, Gansu, Guangdong and Hebei, with the scale of Henan, Hebei, Shandong and Anhui accounting for 86%.

  New Huangpu: planning for non-public offering of shares

  The new Huangpu announced that the company intends to issue shares to no more than 35 specific investors in a non-public manner, and the raised funds are intended to be used for the development and construction of real estate projects related to the company’s "guarantee of property and people’s livelihood", old city reconstruction projects, long-term rental projects, and supplementary liquidity and debt repayment that meet the requirements of the refinancing policy of listed companies.

  Zhuang Kejie, secretary of the board of directors of Shangji CNC, completed the implementation of the reduction plan of 13,600 shares.

  () Announcement was issued. On December 22, 2022, the company received a notice from Mr. Zhuang Kejie, Secretary of the Board of Directors, that Mr. Zhuang Kejie’s shareholding reduction plan had been implemented. On December 22, 2022, Mr. Zhuang Kejie, secretary of the board of directors of the company, reduced his holdings of 13,600 shares of the company by centralized bidding, accounting for 0.0033% of the company’s total share capital. After the reduction, Mr. Zhuang Kejie still holds 41,000 shares of the company, accounting for 0.0100% of the total share capital of the company.

  Guangsheng Nonferrous Metals Co., Ltd. plans to set up a joint venture company to promote the development of mineral resources

  () Announced that the Company has signed an Investment Cooperation Agreement with Zhuhai Runfei Mining Co., Ltd. (hereinafter referred to as Runfei Mining) and Zhuhai Fuhong Investment Co., Ltd. (hereinafter referred to as Fuhong Investment), and plans to jointly promote the production, operation and development of Wengyuan Hongling Mining Co., Ltd. (hereinafter referred to as Hongling Company) through the establishment of Guangdong Shengfeng Resource Development Co., Ltd., so as to promote Hongling Company to actively seek for mining rights.

  The investment scale of the joint venture company is 868 million yuan and the registered capital is 425 million yuan. The company invested RMB 443 million by holding 100% equity of Hongling Company, of which RMB 217 million was included in the registered capital of the joint venture company, so the company holds 51% equity of the joint venture company. Fuhong Investment contributed 425 million yuan in cash, of which 208 million yuan was included in the registered capital of the joint venture company, so Fuhong Investment holds 49% equity of the joint venture company. Except the registered capital, other contributions totaled 443 million yuan, all of which were included in the capital reserve of the joint venture company.

  The signing of this investment cooperation agreement marks the successful completion of the public investment invitation for the mineral resources development project of Hongling Company, which lays the foundation for further implementing the resources development strategy of Hongling Company, is an important measure for the company to further improve and upgrade the industrial development layout, and meets the requirements of the company’s overall development strategy.

  China CNOOC: The wholly-owned subsidiary plans to purchase 40% equity of CNNC Huihai for 1.518 billion yuan.

  China CNOOC announced on the evening of December 22nd that New Energy Company, a wholly-owned subsidiary of CNOOC, plans to purchase 40% equity of CNNC Huihai Wind Power Investment Co., Ltd. (hereinafter referred to as "CNNC Huihai") held by Donghai Company, a wholly-owned subsidiary of CNOOC, the actual controller of the company. After the transaction is completed, New Energy Company will hold 40% equity of CNNC Huihai, and CNNC Huihai will become the company’s shareholding company.

  China Resources Sanjiu: The acquisition and holding of Kunyao Group was approved by the State Council State-owned Assets Supervision and Administration Commission.

  () On the evening of December 22nd, the State-owned Assets Supervision and Administration Commission of the State Council agreed in principle to the overall plan of China Resources Sanjiu to acquire the controlling stake in Kunyao Group by acquiring () 3,335,500 shares held by Huali Group Co., Ltd. and 209 million shares held by Huali Pharmaceutical Group Co., Ltd..

  Huachuang Yang ‘an: 6% equity of Huachuang Securities has been pledged to CSI Credit.

  () Announcement: In March, the board of directors of the company decided to pledge no more than 10% equity of Huachuang Securities to CSI Credit Financing Guarantee Co., Ltd. to provide financing guarantee services for corporate bond issuance. Recently, the company has pledged 6% of the equity of Huachuang Securities to CSI Credit, and received the Notice of Registration for the Establishment of Equity Pledge issued by Guizhou Provincial Market Supervision Administration.

  Huachuang Yangan said that this equity pledge will not have a significant impact on the company’s operation and financial situation, and the risks are controllable, and there is no harm to the interests of the company and all shareholders.

  Hainan Rubber received compensation of 50,620,500 yuan from rubber income insurance.

  () Announced that according to the Insurance Agreement of Hainan Rubber Income Insurance Project in 2022 signed by the company with China People’s Property Insurance Co., Ltd. Hainan Branch and China Pacific Property Insurance Co., Ltd., the insurance compensation conditions were triggered due to price fluctuation in September 2022, and the amount of insurance compensation was determined to be 50,620,500 yuan through three-party investigation and loss determination. Recently, the company has received the above compensation, and the accounting is included in other income.

  The commercial group, the controlling shareholder of Ginza Co., Ltd., completed the increase of about 1% of the company’s shares at a cost of 27.31 million yuan.

  () Announcement: From June 23 to December 22, 2022, Shandong Commercial Group Co., Ltd. ("Commercial Group"), the controlling shareholder of the company, increased its holding of 5,200,700 shares, accounting for about 1%, with a total holding amount of RMB 27,305,600 and an average holding price of RMB 52,504 per share. The implementation of the increase plan expires and the increase plan has been completed.

  35,970,900 restricted shares of Pingao will be listed and circulated on December 30th.

  Pingao shares announced that the number of shares that have been released from restricted sales and applied for listing and circulation this time is 35,970,900 shares, accounting for 31.82% of the company’s total share capital. This part of restricted shares will be listed and circulated on December 30, 2022.

  Jiacheng International: Hengshang Investment intends to reduce its shareholding by no more than 2%.

  Jiacheng International announced on the evening of December 22 that Guangdong Hengshang Investment Management Co., Ltd. (hereinafter referred to as "Hengshang Investment"), a shareholder holding 7.95% of the company’s shares, intends to reduce its shareholding by no more than 2%.

  Aohua Endoscopy awarded 260,000 restricted shares to 8 incentive targets.

  Aohua Endoscope issued an announcement, and the company reviewed and approved the Proposal on Granting Reserved Restricted Shares to the Incentive Objects of the 2022 Restricted Stock Incentive Plan, and determined December 21, 2022 as the reserved grant date, with the grant price of 22.31 yuan/share, and granted 260,000 restricted shares to eight incentive objects that met the conditions for the reserved grant.

  Guangsheng Nonferrous Metals Co., Ltd.: Signing an investment cooperation agreement to promote the development of Wengyuan Hongling mining industry

  Guangsheng Nonferrous announced on the evening of December 22nd that the company had signed investment cooperation agreements with Runfei Mining and Fuhong Investment, and planned to jointly promote the production, operation and development of Wengyuan Hongling Mining Co., Ltd. through the establishment of Guangdong Shengfeng Resources Development Co., Ltd.. The investment scale of the joint venture company is 868 million yuan and the registered capital is 426 million yuan. The company invested 443 million yuan with 100% equity of Hongling Company, of which 217 million yuan was included in the registered capital, so it holds 51% equity of the joint venture company. The signing of this cooperation agreement indicates that the company has successfully completed the public investment invitation for the mineral resources development project of Hongling Company.

  Space-time Technology: Winning the bid for the construction project of taxi service management platform of taxi network.

  Space-time Technology announced on the evening of December 22nd that the company won the bid for the construction project of taxi service management platform of Urumqi Chengtou Urban Construction Resources Development Co., Ltd., with a bid price of 192 million yuan and a cooperation period of 21 years. The construction period is 1 year and the operation period is 20 years. The bid amount accounts for about 25.72% of the company’s annual operating income in 2021.

  Guangzhou Houbao, the shareholder of Tebao Bio, completed the reduction and accumulated a reduction of 299,900 shares.

  Tebao Bio announced that Guangzhou Houbao, the shareholder of the company, has completed the implementation of the centralized bidding transaction reduction plan, with a cumulative reduction of 299,900 shares.

  Jiufeng Energy shareholder Shidai Finance intends to reduce its holdings by no more than 349,000 shares.

  () Announcement is issued. Shareholder Shidai Finance plans to reduce its holdings of the company’s shares by no more than 349,000 shares (inclusive) through centralized bidding and/or block trading, accounting for 0.0563% of the company’s total share capital, and the reduction price is not less than 24.39 yuan/share.

  Jin Yan, supervisor of Warner Pharmaceutical Factory, completed the implementation of the reduction plan of 660,400 shares.

  Warner Pharmaceutical Company announced that as of December 22, 2022, Mr. Jin Yan, the company’s shareholder and supervisor, had reduced the company’s shares by 660,400 shares through centralized bidding, accounting for 0.70% of the company’s total share capital, and the above reduction plan was completed.

  Yongji Co., Ltd.: It is planned to set up a wholly-owned subsidiary to develop packaging and printing related business.

  () On the evening of December 22nd, it was announced that it planned to set up Guizhou Qiannan Yongji Printing Co., Ltd., a wholly-owned subsidiary in Qiannan, Guizhou Province, with 50 million yuan to further develop packaging and printing related business and launch new project business.

  Jiufeng Energy: Shidai Finance plans to reduce its shareholding by no more than 0.06%.

  Jiufeng Energy announced on the evening of December 22nd that Starr Financial (Barbados) I, Inc (hereinafter referred to as "Shidai Finance"), the shareholder holding 6.0373% of the company’s shares, plans to reduce the company’s shares by no more than 0.0563% at a price of no less than 24.39 yuan per share.

  Renfu Medicine corrects and retroactively adjusts the previous accounting errors.

  On the evening of December 22nd, () issued an announcement, and the company recently held a board meeting and a board of supervisors to review and approve the Proposal on Correction and Retroactive Adjustment of Accounting Errors in the Company’s Early Period, so as to retroactively adjust the company’s consolidated financial statements from 2017 to 2021 and the financial statements of the parent company, and at the same time correct the consolidated financial statements and the financial statements of the parent company in the first three quarters of 2022.

  According to the announcement, the board of directors, independent directors and the board of supervisors of Renfu Pharmaceutical gave their consent to the correction and retrospective adjustment of accounting errors. The Board of Directors and the Board of Supervisors of the Company agreed that the correction and retrospective adjustment of accounting errors in the previous period were in line with the provisions of Accounting Standards for Business Enterprises No.28-Changes in Accounting Policies and Accounting Estimates and Error Correction, and China Securities Regulatory Commission’s Rules for the Compilation of Information Disclosure of Companies Offering Securities to the Public No.19-Correction and Related Disclosure of Financial Information, which could reflect the company’s financial position and operating results more objectively and fairly, and there was no harm to the rights and interests of the company and shareholders.

  On the day of the announcement, Daxin Certified Public Accountants issued an opinion on the audit report on the correction of accounting errors in the previous period and the retrospective adjustment. On the same day, Renfu Medicine also disclosed the revised annual report for 2021, the first quarter report for 2022, the semi-annual report for 2022 and the third quarter report for 2022 on the website of Shanghai Stock Exchange.

  The relevant person in charge of Renfu Medicine said that after the correction and retrospective adjustment of accounting errors in the previous period, the company will not have a significant impact on the company’s assets and performance by including related companies in the scope of consolidated statements. After several years of business integration and business development, the quality of related assets is generally good, and the company will continue to operate as planned, sell as soon as possible, or cancel according to procedures; On the other hand, it can ensure the safety of related assets and fully resolve the long-term uncollected risks of other receivables, which is conducive to improving the overall asset quality of listed companies and achieving more efficient and stable development of their core business.

  Through the correction and retrospective adjustment of accounting errors in the previous period, although the corresponding financial indicators of Renfu Pharmaceutical have changed in the past three years, the first quarter report in 2022, the semi-annual report in 2022 and the third quarter report in 2022, the overall business performance and net profit growth trend of listed companies in the past three years have not been affected. Especially in recent years, the company has made continuous breakthroughs in innovative drugs, showing a more stable development trend. (Cheng Wei)

  Jiamao Information, the shareholder of Yongxin Optics, intends to reduce its holdings by no more than 400,000 shares.

  () Announced that the shareholder Jiamao Information plans to reduce the company’s shares by means of centralized bidding, block trading and other laws and regulations, and the total amount of reduction will not exceed 400,000 shares within six months after three trading days from the date of disclosure of this reduction plan announcement, accounting for 0.362% of the company’s total share capital.

  Heyuan Bio won the real estate at No.19, Lane 908, Ziping Road, Pudong New Area, Shanghai for 98.69 million yuan.

  Heyuan Bio-announcement, previously disclosed that the company intends to participate in bidding for the real estate ("the underlying assets") at No.19, Lane 908, Ziping Road, Pudong New Area, Shanghai, owned by Shanghai () Park Joint Development Co., Ltd. with its own funds and self-raised funds.

  It is reported that the underlying assets are state-owned assets, and the underlying assets were listed on the Shanghai United Assets and Equity Exchange for public transfer on November 9, 2022. By the end of this bidding, the company, as the effective highest bidder for this bidding, has successfully bid, and the quoted amount is RMB 98,687,075. Recently, the company signed the "Shanghai Real Estate Sales Contract" with Shanghai International Medical Park Joint Development Co., Ltd., with a contract transaction amount of RMB 98,687,075.

  Huiyu Pharmaceutical Co., Ltd.: Paclitaxel Injection was approved for marketing in Germany.

  Huiyu Pharmaceutical announced on the evening of December 22nd that Seacross Pharma (Europe) Limited, a wholly-owned subsidiary, recently received a marketing license for its product paclitaxel injection approved by the German Food and Drug Administration. Paclitaxel injection is suitable for the first-line and subsequent treatment of advanced ovarian cancer.

  Energy-saving wind power: it is planned to invest a total of 2.617 billion yuan in four wind power projects.

  Energy-saving wind power announcement: the company plans to invest in the establishment of China Energy Saving Laifeng Wind Power Generation Co., Ltd. and China Energy Saving Xianfeng Wind Power Generation Co., Ltd., and invest in the construction of China Energy Saving 250,000 kW wind storage integration (Phase I) project in Xiangzhou, Hubei Province, China Energy Saving 110MW wind power project in Suzhou and Dengzhou, China Energy Saving 50MW wind power project in Tianshui and Qin Zhou, and China Energy Saving 100MW wind power project in Jiu Hao Town of Songxian County. The total investment of the above wind power projects is 2,616,010,000 yuan.

  Shanghai Tewo, the major shareholder of Northern Shares, reduced its holdings by 2%.

  () Announcement: Tewo (Shanghai) Enterprise Management Consulting Co., Ltd. ("Shanghai Tewo"), a shareholder holding more than 5% of the company’s shares, reduced its shareholding by 3.4 million shares on December 22, 2022, accounting for 2% of the company’s total share capital, and its shareholding ratio decreased from 25.16% to 23.16%.

  Swan shares: stock price changes will be suspended for verification from December 23.

  () It was announced on the evening of December 22nd that from October 31st to the close of December 22nd, the company’s stock had a total daily limit of 16 trading days, hitting four abnormal fluctuations, and the stock price rose by 175.32%. The company’s stock was suspended from the market opening on December 23rd, and resumed trading after the verification announcement was disclosed.

  Shentong Technology granted 450,000 restricted shares to 40 incentive targets.

  () Announcement was issued. The Board of Directors considered that the reserved grant conditions stipulated in the Company’s Restricted Stock Incentive Plan 2021 (Revised Draft) had been achieved, and agreed to set December 22, 2022 as the reserved grant date, and granted 450,000 restricted shares to 40 incentive targets meeting the grant conditions at a price of 4.62 yuan per share.

  Swan shares applied for stock trading suspension verification, and suspended trading since the market opened on December 23.

  Swan announced that the company’s stock price has recently increased significantly. From October 31, 2022 to the close of December 22, the company’s stock has accumulated a total of 16 trading days, hitting four abnormal fluctuations, and the stock price has increased by 175.32%. In view of the recent volatility of the company’s share price, in order to safeguard the interests of investors, the company checked the fluctuation of stock trading. Upon the application of the company, the company’s stock (stock abbreviation: Swan shares; Stock code: 603029) Suspension of trading since the market opened on December 23, 2022, and resumption of trading after disclosure of the verification announcement.

  Swan shares: Recently, it has touched four times of abnormal fluctuations and the stock has been suspended for verification.

  Swan shares announced that from October 31, 2022 to the close of December 22, the company’s stock has accumulated a total of 16 trading days, hitting four abnormal fluctuations, and the stock price has increased by 175.32%, and the stock has been suspended for verification.

  CITIC Jiantou Jing Rong Bond Fund raised in advance.

  On the 22nd, () Jing Rong Bond Fund announced that it began to raise funds on December 15th. At present, both the total fund shares and the number of subscribers have reached the filing conditions for the fund contract to take effect, and it was decided to advance the deadline for raising funds from March 14th, 2023 to December 21st, 2022, and no subscription applications will be accepted from December 22nd (including that day).

  Huiyu Pharmaceutical: Anti-cancer drug "Paclitaxel Injection" was approved for marketing in Germany.

  Huiyu Pharmaceutical announced that Seacross Pharma (Europe) Limited, a wholly-owned subsidiary of the company, recently received a marketing license for the company’s product paclitaxel injection approved and issued by the German Federal Agency for Drugs and Medical Devices ("German Food and Drug Administration").

  It is reported that paclitaxel injection is suitable for the first-line and subsequent treatment of advanced ovarian cancer; Adjuvant treatment of breast cancer patients with lymph node positive after standard chemotherapy with adriamycin; Breast cancer patients with metastatic breast cancer who failed in combination chemotherapy or relapsed within 6 months after adjuvant chemotherapy; First-line treatment of patients with non-small cell lung cancer and second-line treatment of Kaposi’s sarcoma associated with AIDS.

  Shanghai Shuangsa, the major shareholder of Huiyu Pharmaceutical, reduced its holdings by 2.37%, and more than half of them were implemented.

  Huiyu Pharmaceutical announced that from November 24 to December 21, 2022, Shanghai Shuangsa Enterprise Management Consulting Firm (Limited Partnership) ("Shanghai Shuangsa"), a shareholder holding more than 5% of the company’s shares, reduced its holdings by 10,031,500 shares, accounting for 2.368% of the company’s total share capital. The number of this reduction plan has been more than half, and the reduction plan has not yet been implemented.

  The stock price has fluctuated greatly recently, and Swan shares have been suspended for verification since December 23.

  On the evening of December 22nd, Swan announced that in view of the recent large fluctuation of the company’s share price, in order to safeguard the interests of investors, the company checked the fluctuation of stock trading. Upon the company’s application, the company’s shares were suspended from the market opening on December 23, and resumed trading after the disclosure of the verification announcement.

  According to the announcement, the stock price of Swan shares has increased significantly recently. From October 31st to the close of December 22nd, the company’s stock has accumulated a total of 16 trading days, hitting four abnormal fluctuations, and the stock price has increased by 175.32%.

  Xinnong Development intends to apply for compulsory execution on the outstanding asset transfer funds of Alar Zhongtai and Korla Zhongtai.

  () Announcement. As disclosed in the previous announcement, Xinnongfa Industrial Investment Management Co., Ltd. ("Xinnongfa Company"), a wholly-owned subsidiary of the company, has transferred all the effective operating assets and supporting facilities (including inventory, fixed assets, construction in progress, intangible assets, etc.) of its production line with an annual output of 80,000 tons of viscose fiber and 100,000 tons of cotton pulp to Alar Zhongtai Textile Technology at a price of 1.17 billion yuan by way of public listing and transfer. Both parties signed the Property Rights Transaction Contract and related Supplementary Contract, and the latest payment date stipulated in the contract is December 30, 2018. As of December 30, 2018, Alar Zhongtai Textile still owes the company 269 million yuan and related interest has not been paid.

  In August, 2020, New Agricultural Development Corporation and Aral Zhongtai reached a pre-litigation mediation and signed a civil mediation document ((2020) Bing 01 Min Chu No.3) according to the Property Right Transaction Contract and Supplementary Agreement signed by both parties and the Letter of Guarantee for Joint Liability issued by Korla Zhongtai Textile Technology Co., Ltd. ("Korla Zhongtai").

  According to the civil mediation agreement, Alar Zhongtai should pay 100 million yuan of assets transfer to the new agricultural development company before December 20, 2022, and actually paid 30 million yuan, and the rest has not been paid. The new agricultural development company intends to apply to the court for enforcement of the unpaid transfer funds of Alar Zhongtai and Korla Zhongtai. According to the relevant provisions of the Accounting Standards for Business Enterprises, it will have a significant negative impact on the company’s performance in 2022, and it is estimated that the provision for bad debts will be about 50 million yuan.

  China UAV: About 7,023,400 restricted shares will be lifted on December 29th.

  China Fortune Connect December 22-China UAV announced that about 7,023,400 restricted shares of the company will be released and listed for circulation on December 29, 2022, accounting for 1.0405% of the company’s total share capital.

  Zhuzhou Smelter Group: The reorganization will be suspended on December 28th.

  () Announcement: The Audit Committee on Mergers and Acquisitions of Listed Companies of China Securities Regulatory Commission ("China Securities Regulatory Commission") is scheduled to hold a working meeting at 9:00 a.m. on December 28th, 2022 to review the company’s issuance of shares, payment of cash to purchase assets, raising matching funds and related transactions. The company’s shares will be suspended on the day of the working meeting of the M&A and Restructuring Committee.

  Haimuxing received a government subsidy of 11.8 million yuan in the past month.

  Haimuxing announced that from November 22, 2022 to December 22, 2022, the company received a total of 11,799,500 yuan of government subsidies, all of which were related to income.

  (): verify the problems listed in the decision of administrative supervision measures of Liaoning Securities Regulatory Bureau and formulate the rectification plan.

  ST Shuguang announced on the evening of December 22nd that after the company received the decision on administrative supervision measures issued by Liaoning Securities Regulatory Bureau, the board of directors attached great importance to it, and immediately notified and conveyed it to all directors, supervisors, senior managers and personnel of relevant departments of the company. On the day of receipt, the company verified the problems listed in the decision, formulated the rectification plan according to the actual situation of the company, and clarified the responsibilities.

  In terms of standardized operation, the Nomination Management Committee of the Board of Directors of the Company will continuously strengthen standardized operation, strictly perform its duties and procedures, and ensure that all senior executives who meet the requirements and conditions of the Company are nominated by the Nomination Committee of the Board of Directors and reviewed by the Board of Directors.

  The remuneration Committee of the company’s board of directors will ensure that the standardized operation is strengthened. The company plans to finalize the business management plan for 2023 in January 2023 and hold a special meeting of the remuneration committee of the board of directors. The main contents of the topic include: according to the requirements, according to the main scope of work, responsibilities and importance of directors and senior management positions and the salary level of related positions in other related enterprises, formulate the salary standards and welfare standards for senior executives in 2023; Review the salary policy and implementation plan of employees in 2023. In addition, it includes the salary policy and implementation plan in 2023, including but not limited to performance evaluation standards, procedures and main evaluation systems, reward and punishment systems and standards; Review the performance of duties of directors and senior managers of the company, and conduct annual performance appraisal for them in 2022.

  The Strategy Committee of the Board of Directors of the Company will study and make suggestions on major projects or contracts such as technical transformation, foreign investment, entrusted wealth management, etc. with a turnover of more than 10 million yuan (excluding this amount) to ensure that the duties of the Strategy Committee of the Board of Directors are fulfilled in place. The company plans to hold a special meeting of the Strategy Committee of the Board of Directors in 2022 in late December, and make research and suggestions on the company’s medium-and long-term strategic planning, so as to guide the company’s medium-and long-term strategic development.

  In terms of information disclosure, the company will do a good job in information disclosure in the future in strict accordance with the requirements of Liaoning Securities Regulatory Bureau, adhere to the continuity and consistency of information disclosure, and may not make selective disclosure.

  ST Shuguang said that the company is deeply aware of the shortcomings in corporate governance and information disclosure, and will seriously and continuously improve its standard operation ability, strengthen internal control supervision and inspection, further improve and improve the governance level and information disclosure quality, earnestly safeguard the legitimate rights and interests of the company and all shareholders, and realize the standardized, sustained, stable and healthy development of the company.

  Southern Power Grid Energy Storage: The main project of Huizhou Zhongdong Pumping and Storage Power Station started on December 23rd.

  Southern Power Grid Energy Storage announced on the evening of December 22nd that Guangdong Huizhou Zhongdong Pumped Storage Power Station Project (referred to as "Huizhou Zhongdong Project") is a key implementation project of Guangdong Province in the "Tenth Five-Year Plan" of the National Energy Administration’s Medium and Long-term Development Plan for Pumped Storage (2021-2035). Huizhou Zhongdong Pumped Storage Power Generation Co., Ltd. is responsible for the investment and construction, and the main project of the project is scheduled to start on December 23rd, 2022. China Southern Power Grid Peak Regulation and Frequency Modulation Power Generation Co., Ltd., a wholly-owned subsidiary of China Southern Power Grid Energy Storage, holds 70% of Huizhou Zhongdong Energy Storage Power Generation Co., Ltd.

  The announcement shows that Huizhou Zhongdong Pumped Storage Power Station is located in Zhongdong Village, Gaotan Town, Huidong County, Huizhou City, with a total installed capacity of 1.2 million kilowatts (3× 400,000 kilowatts). After the completion of the power station, it will play an important role in promoting the large-scale development of clean energy such as wind power and photovoltaics, optimizing the power supply structure and ensuring the safe, stable and economic operation of the power system. The main construction contents of the project are upper reservoir, lower reservoir, water conveyance and power generation system, switching station, etc., with an estimated investment of 8.373 billion yuan.

  Betray, the shareholder of Fangyuan, has reduced his holdings by 1.34%.

  Fangyuan shares issued an announcement. On December 22, 2022, the company received the Notice Letter on Changes in Equity issued by the company’s shareholder Betray New Materials Group Co., Ltd. (hereinafter referred to as "Betray"), and learned that it reduced its holdings of the company’s shares by block trading on December 22, 2022, accounting for 1.34% of the company’s total share capital.

  Faced with major illegal forced delisting *ST Amethyst part of the draft is overdue.

  On the 21st, *ST Amethyst issued a risk warning announcement, and the company’s stock price increased significantly on December 20th, 2022. At the same time, the announcement disclosed a number of risk warnings, including the overdue of some commercial acceptance bills and bank acceptance bills issued by the company, and the possibility that the company may touch on major illegal acts stipulated by the exchange, and there is a risk of major illegal forced delisting.

  The announcement shows that some commercial acceptance bills and bank acceptance bills issued by *ST Amethyst are overdue. By December 20, 2022, the total face value of overdue bills was 189.3981 million yuan, the company had paid a total of 19.8268 million yuan, and the overdue amount was 169.5713 million yuan, accounting for 6.42% of the company’s audited total assets at the end of 2021 and 10.76% of the net assets attributable to shareholders of listed companies. According to the Company, the above-mentioned overdue items may lead to the decline of the company’s financing ability, the related financial institutions may demand early repayment and file lawsuits against overdue items, and the aging period of suppliers’ payment to the company may be shortened, further aggravating the company’s financial shortage and having a negative impact on the company’s daily operations. The company may face the payment of related liquidated damages, penalty interest, etc., which will lead to the increase of the company’s financial expenses, and then have a certain impact on the company’s current profit or future profit.

  *ST Amethyst also disclosed that it has the risk of major illegal forced delisting. On February 11, 2022, the company received the Notice of Filing from China Securities Regulatory Commission, and the actual controllers Zheng Mu and Luo Tiewei received the Notice of Filing from China Securities Regulatory Commission on June 24, 2022. China Securities Regulatory Commission decided to file an investigation on the company, Zheng Mu and Luo Tiewei because of the alleged violation of information disclosure. On November 18, 2022, the company received the Advance Notice of Administrative Punishment and Market Prohibition from China Securities Regulatory Commission. According to the confirmation in the Advance Notice, the company may touch the major illegal act stipulated in Article 12.2.2 of the Listing Rules of science and technology innovation board Stock Exchange (revised in April 2019 and revised in December 2020), and there is a risk of mandatory delisting due to major illegal acts.

  In addition, *ST Amethyst was suspected of failing to disclose 417.9 million yuan of external guarantees in time in 2021, accounting for 22.46% of the latest audited net assets. Up to now, the company’s guarantee funds have been deducted or frozen, which has caused the company to confirm its estimated liabilities and losses. In the future, if the company can’t release the guarantee pledge, and the borrower or other guarantors can’t bear the relevant debts, it may cause the company’s credit and cash flow to be tight, which may further lead to the risks of limited business development and employee turnover, which will affect the company’s ability to continue to operate.

  Moreover, Zheng Mu and Luo Tiewei, the actual controllers of *ST Amethyst, still have large personal debts and pending litigation matters, and their wholly-owned shares of Meizhou Zichen and Meizhou Zihui are 100% pledged, and the indirectly held shares of the company are 100% pledged. If the actual controllers cannot raise funds to solve debt and litigation problems in the future, it may lead to the risk of changes in the actual control rights of the company in the future.

  *ST Zijing’s 2021 financial report auditing agency Zhongxi Certified Public Accountants issued an audit report on the company’s financial statements in 2021 that could not express opinions. Up to now, the company can’t express opinions in 2021, and the matters involved in the audit report of financial statements have not been resolved; The company’s internal control audit report with negative opinions in 2021; There are four directors in the company who cannot guarantee the authenticity, accuracy and completeness of the contents of the semi-annual report in 2022 and the third quarterly report in 2022.

  Shanwaishan will be listed in science and technology innovation board on December 26th.

  Shanwaishan announced that the company’s shares will be listed on the science and technology innovation board Stock Exchange on December 26th, 2022.

  Rebate Technology completed the repurchase of 90,534,400 shares, and the performance promised compensation shares accounted for 11% of the total share capital.

  () Announcement: According to the resolution of the 2021 Annual General Meeting of Shareholders, the Profit Forecast Compensation Agreement for Major Asset Restructuring and its supplementary agreement, the company repurchased 90,534,400 shares at a total price of RMB 0.97 as of the disclosure date of the announcement, accounting for 11.00% of the company’s total share capital. According to relevant regulations, the company will cancel the aforesaid shares, and the cancellation of share repurchase will not lead to any change in the company’s control rights.

  Shanghai Xiba: Termination of the transfer of 100% shares of Bodu Technology

  Shanghai Xiba announced that Gongcheng Environment, a wholly-owned holding company of the company, planned to transfer 100% shares of Zhejiang Bodu Technology Co., Ltd. to Jiuting City Ring for 146 million yuan. Due to the failure of the relevant transaction plan to get the clear support of the land supervision department and the comprehensive influence of other factors, both parties agreed to terminate the equity transfer cooperation agreement signed in the early stage.

  Nanshan aluminum: It is planned to transfer the capacity index of 336,000 tons of electrolytic aluminum.

  Nanshan aluminum announced that the company plans to transfer 336,000 tons of electrolytic aluminum production capacity index. After evaluation, the value of this production capacity index is about 2.227 billion yuan. It is estimated that after deducting various taxes and fees, this transaction will gain 1.773 billion yuan in transfer income, accounting for more than 50% of the latest audited net profit.

  Chengdu gas: elected Wang Shouhao as the chairman of the company.

  Chengdu Gas announced tonight that the company held the 21st meeting of the second board of directors today, and reviewed and approved the Proposal on Electing the Chairman of the Second Board of Directors and the Proposal on Electing Members of Special Committees of the Second Board of Directors. The board of directors of the company elected Wang Shouhao as the chairman of the company, elected him as a member of the strategy committee of the second board of directors of the company, nominated him as a member of the strategy committee and served as the convener of the strategy committee, with the term of office from the date of deliberation and approval by the board of directors to the date of expiration of the term of office of the second board of directors.

  Resume of Wang Shouhao:

  Wang Shouhao, male, born in party member, CPC, in July 1979, is of China nationality and has no permanent residency abroad, with a master’s degree. He is currently the secretary, director and chairman of the Party Committee of Chengdu Gas Group Co., Ltd., and has served as the office staff, second-class manager, deputy director and director of the board office of Chengdu Urban Construction Investment Management Group Co., Ltd., the secretary of the first party branch of the group headquarters, and the member, secretary, director and chairman of the party branch of Chengdu Tianfu Olympic Sports City Investment Development Co., Ltd.

  Shareholders of Jiacheng International intend to reduce their holdings by no more than 2%.

  Jiacheng International announced that the shareholder Hengshang Investment intends to reduce the company’s shares by no more than 2% of the company’s total share capital.

  Swan shares: stock price change suspension verification

  Swan shares announced that the company’s stock price has recently increased significantly, and the company intends to check the fluctuation of stock trading. The company’s shares have been suspended since the market opened on December 23, 2022, and resumed trading after the disclosure of the verification announcement.

  China CNOOC: The subsidiary plans to acquire 40% equity of CNNC Huihai for 1.518 billion yuan.

  China CNOOC announced that New Energy Company, a wholly-owned subsidiary of CNOOC, plans to purchase 40% equity of CNNC Huihai Wind Power Investment Co., Ltd. (hereinafter referred to as "CNNC Huihai") held by Donghai Company, a wholly-owned subsidiary of CNOOC, the actual controller of the company, for 1.518 billion yuan. CNNC Huihai is mainly engaged in wind power and photovoltaic power generation business investment. After the transaction is completed, the new energy company will hold 40% equity of CNNC Huihai, and CNNC Huihai will become the company’s shareholding company.

  Jianfa Hecheng: Some senior executives plan to increase their shares by not less than 10 million yuan.

  Jianfa Hecheng announced that four people, including Vice Chairman and President Huang Hebin, Vice Presidents Liu Zhixun and Xu Hui, and Secretary of the Board of Directors Gao Weilin, plan to increase their shares in the company by centralized bidding with their own funds within six months from December 26, 2022, with a total amount of not less than 10 million yuan.

  Huayou Cobalt: GDR was issued and listed on the Swiss Stock Exchange and approved by the Swiss Stock Exchange Supervision Bureau.

  Huayou Cobalt announced that the company recently obtained the conditional approval from the Swiss Stock Exchange Regulatory Authority on the issuance of global depositary receipts (GDR) and listing on the Swiss Stock Exchange. The Swiss Stock Exchange Regulatory Authority agreed that the GDR issued by the company should be listed on the Swiss Stock Exchange after meeting the customary conditions.

  Xianghe Industry: It is planned to delist 6.6% equity of Zhongyuan Lida.

  Xianghe Industry announced that General Technology was publicly listed on the Beijing Equity Exchange to transfer 6.60% equity of Zhongyuan Lida Railway Track Technology Development Co., Ltd. (referred to as "Zhongyuan Lida"). The company participated in the public delisting of 6.60% equity of Zhongyuan Lida and was confirmed as the final transferee. The transaction price was 48 million yuan. Zhongyuan Lida is one of the few companies in the industry with core technology and the qualification to produce and supply key parts of high-speed rail fastener system. Xianghe Industrial shares in Zhongyuan Lida, which can produce good synergy and form the same frequency resonance in business development.

  Sinopharm Hyundai: its subsidiary has obtained the registration certificate of cytarabine for injection.

  Sinopharm Modern announced that Sinopharm, a holding subsidiary, wholeheartedly received the registration certificate of cytarabine for injection approved and issued by National Medical Products Administration. Cytarabine for injection is an antimetabolic drug, which is mainly suitable for the induction, remission and maintenance treatment of acute non-lymphocytic leukemia in adults and children.

  Otway: Won the bid for the 155 million yuan all-in-one welding project.

  Aotewei announced that the company has obtained a bid-winning notice for the "All-in-one Welding Project" of New Energy Technology (Quzhou) Co., Ltd., with a total bid amount of about 155 million yuan.

  Huaqin Technology plans to spend 66.54 million yuan to purchase related real estate to reduce related transactions.

  Huaqin Technology announced that the company plans to purchase Building No.4 held by Shaanxi Huaqin New Energy Technology Co., Ltd. at No.188, West Avenue, High-tech Zone, Xi ‘an City, Shaanxi Province and its corresponding land use rights with self-raised funds of 66.5434 million yuan (including tax). Shaanxi Huaqin New Energy Technology Co., Ltd. is a company directly controlled by Zhe Shengyang, the actual controller and chairman of the company, and serves as a director.

  The announcement shows that most of the assets related to Shaanxi Huaqin New Energy Technology Co., Ltd. to be purchased this time are currently leased by the company, and the rental fee is about 3.9 million yuan per year. This transaction can further reduce the related transactions between the company and related parties.

  Lexus Software plans to buy back shares with its own funds not exceeding 200 million yuan.

  On the evening of December 22nd, Lexus Software announced that it planned to use its own funds of no more than 200 million yuan to buy back the company’s shares by centralized bidding, and the repurchase price was no more than 16.30 yuan/share (inclusive). The implementation period of share repurchase is within 12 months from the date when the company’s board of directors deliberated and approved this share repurchase plan, and all the repurchased shares will be used for employee stock ownership plan or equity incentive at an appropriate time in the future.

  According to the announcement, the repurchase plan was proposed by Mr. Zhang Baoquan, the company’s chairman, controlling shareholder and actual controller. He said that based on the confidence in the future development of the company and the recognition of the company’s long-term value, in order to safeguard the interests of investors, improve the company’s long-term incentive mechanism, and more closely and effectively combine the interests of shareholders, the company’s interests and employees’ personal interests to promote the healthy and sustainable development of the company, it is proposed to use the company’s own funds to buy back the company’s shares for subsequent employee stock ownership plans or equity incentives.

  According to the company’s third quarterly report, as of September 30, 2022, the company’s total assets were 1.353 billion yuan, net assets attributable to shareholders of listed companies were 1.270 billion yuan, and current assets were 959 million yuan. If calculated according to the upper limit of 200 million yuan for this repurchase, it accounts for 14.78%, 15.75% and 20.86% of the above financial data respectively.

  The company said that this share repurchase will further improve the company’s long-term incentive mechanism and effectively combine the personal interests of the company, shareholders and employees, which is conducive to safeguarding the interests of investors and promoting the company’s high-quality development. At the same time, according to the company’s operation and future development plan, this repurchase will not have a significant impact on the company’s operation, finance, research and development and future development, and the company has the ability to pay the repurchase price.

  Some analysts believe that the company’s implementation of repurchase releases a positive signal and conveys to the market that the company has long-term investment value, which is conducive to safeguarding the company’s value and shareholders’ rights and interests, and enhancing and boosting investor confidence. It is worth noting that Lexus Software has been paying attention to returning investors since its listing, and has maintained a good dividend level. In recent three years, the annual cash dividend amount has reached 80,002,000 yuan.

  The company said that in the future, based on the application of emerging technologies such as cloud computing, big data, artificial intelligence and blockchain in the financial industry, it will continue to deepen R&D and innovation, continuously enhance the company’s core competitiveness and sustainable profitability, enhance corporate value, and strive to return investors with good business performance. (Qi Hening)

  Aozhe shares: shareholder Miao Yu holds 250,000 shares of the company.

  Aozhe announced on December 22, 2022 that on December 22, 2022, Mr. Miao Yu increased his holding of 250,000 shares in the national share transfer system for small and medium-sized enterprises through block trading.

  Financial Tips of Tongbi: According to public data, the operating income of Aozhe in 2021 was 3,055,604 yuan, the net profit attributable to the parent company was-1,832,033 yuan, the return on net assets was -48.51%, and the growth rate of operating income was -19.11%. At present, the sponsoring brokerage firm is Founder Securities, and the trading method is call auction Trading, which belongs to the basic level.

  Guangsheng Nonferrous Metals Co., Ltd.: It is planned to set up a joint venture company to promote the development of Wengyuan Hongling mining industry.

  Guangsheng Nonferrous announced that the company has signed investment cooperation agreements with Runfei Mining and Fuhong Investment, and plans to jointly promote the production, operation and development of Wengyuan Hongling Mining Co., Ltd. by establishing a joint venture company, Guangdong Shengfeng Resources Development Co., Ltd. The investment scale of the joint venture company is 868 million yuan and the registered capital is 426 million yuan. The company invested 443 million yuan with 100% equity of Hongling Company, of which 217 million yuan was included in the registered capital, so it holds 51% equity of the joint venture company. On this basis, Runfei Mining and Fuhong Investment jointly invested to set up a project company, and obtained the right to treat and sell products such as stope weathered sand, waste rock and tailings of concentrator in Hongling Project with compensation, and assumed the responsibility for its own profits and losses. The signing of this cooperation agreement indicates that the company has successfully completed the public investment invitation for the mineral resources development project of Hongling Company.

  Huiyu Pharmaceutical: Taxol injection, a subsidiary, was approved for marketing in Germany.

  Huiyu Pharmaceutical announced that Seacross Pharma(Europe)Limited, a wholly-owned subsidiary, recently received a marketing license for the company’s product paclitaxel injection approved by the German Food and Drug Administration.

  China CNOOC expanded its new energy business by over 1.5 billion yuan to purchase 40% equity of CNNC Huihai.

  On December 22nd, China CNOOC announced that its wholly-owned subsidiary plans to purchase 40% equity of CNNC Huihai Wind Power Investment Co., Ltd. with its own funds of about RMB 1.518 billion.

  According to reports, CNNC Huihai is mainly engaged in wind power and photovoltaic power generation business investment. China CNOOC said that the transaction can effectively promote the company’s business expansion and talent training in the field of new energy, and effectively promote the company’s green and low-carbon transformation and high-quality development.

  Sino Medical: Coronary balloon products have been certified by FDA (510).

  Sino Medical announced that the company recently received a notice from the US FDA that the company’s NC ROCKSTAR non-compliant balloon dilation catheter was certified by the FDA (510(k)). This product is suitable for balloon catheter dilation for patients with atherosclerosis to improve myocardial perfusion and for autologous coronary artery or bypass stenosis. This product is also suitable for balloon stent (bare metal and drug-eluting stent) after delivery.

  (): On 22nd, the manager of the company received about 18,866,900 yuan of reorganization investment corresponding to the difference in asset disposal.

  On the evening of December 22, *ST Fangke announced that on December 22, 2022, the company manager received a reorganization investment of RMB 18,866,919.76 corresponding to the asset disposal difference. As of the date of announcement, the company manager has received a total of RMB 70 million from the auction and the balance of assets disposal.

  Daheng Technology: The equity of the company held by Zheng Suzhen, the controlling shareholder of the company, has been continuously frozen.

  On December 22nd, () issued an announcement about the continued freezing of the controlling shareholder’s equity. According to the announcement, Daheng New Era Technology Co., Ltd. (hereinafter referred to as "the company") received the Notice of Judicial Freeze and Judicial Transfer of Equity from China Securities Depository and Clearing Co., Ltd. Shanghai Branch (hereinafter referred to as "Zhongdeng Shanghai Branch") on December 22, 2022. Qingdao Intermediate People’s Court of Shandong Province served Zhongdeng Shanghai Branch with the Notice of Assistance in Execution ((2016) No.148 of L02 Criminal Court). According to the contents of the freezing order No.148 of L02 Criminal Court of Qingdao Intermediate People’s Court of Shandong Province, the 129,960,000 unrestricted shares of the Company held by Ms. Zheng Suzhen, the controlling shareholder of the company, continued to be frozen, and the freezing period was from 2022. This renewal includes fruits (referring to the share delivery, share transfer and cash bonus distributed through Zhongdeng Shanghai Branch).

  Tonghua dongbao: THDBH151 tablets were approved for clinical application.

  Tonghua dongbao announced on the evening of December 22nd that Dongbao Zixing, a wholly-owned subsidiary of the company, had recently obtained the approval notice on the clinical trial of THDBH151 tablets issued by National Medical Products Administration Drug Evaluation Center.

  Tonghua dongbao said that in recent years, the number of patients with gout and hyperuricemia in China has obviously increased and become younger. Hyperuricemia has become the "fourth highest" after diabetes, hypertension and hyperlipidemia, and gout has become the second largest metabolic disease after diabetes. At present, drugs for treating gout mainly include xanthine oxidase inhibitors (allopurinol, febuxostat) with XO as the main target, and Urat1 inhibitors (benbromarone, resinad) which inhibit uric acid reabsorption. There is room for improvement in the effectiveness and safety of these two kinds of drugs.

  Tonghua dongbao said that THDBH151 tablet is a double-target inhibitor of gout, because of its special advantages in mechanism, it can not only inhibit xanthine oxidase (XO), reduce uric acid production from the source, but also inhibit the reabsorption of uric acid by URAT1 transporter in renal tubules and accelerate uric acid excretion. In addition, THDBH151 tablets can balance the function of XO/Urat1 in reducing uric acid, improve the efficacy and reduce the side effects, and greatly improve the patient’s compliance, which is expected to become a Bestin-Class drug in the same field. At present, there are no similar products listed at home and abroad.

  Kangwei Century: The first domestic kit for detecting Helicobacter pylori fecal nucleic acid was successfully listed.

  On the evening of December 22nd, Kangwei Century announced that the Helicobacter pylori nucleic acid detection kit independently developed and produced by the company was recently awarded the Medical Device Registration Certificate (Registration CertificateNo.: 20223401755) issued by National Medical Products Administration, which is the first Class III registration certificate for Helicobacter pylori nucleic acid detection based on fecal samples in China, filling the gap in the industry and seizing the high ground.

  It is reported that as early as 1994, the National Cancer Research Institute under WHO defined Helicobacter pylori as a class I carcinogen. In 2021, the 15th edition of the carcinogen report published by the US Department of Health and Human Services added Helicobacter pylori as a definite carcinogen. Helicobacter pylori infection is the most important risk factor for gastric cancer. The infection rate of Helicobacter pylori in Chinese population is as high as 40% ~ 60%. Helicobacter pylori infection will cause chronic inflammation and significantly increase the risk of duodenal and gastric ulcer diseases and gastric cancer. The Expert Consensus on Helicobacter Pylori Eradication and Gastric Cancer Prevention and Control in China (Shanghai, 2019) has made it clear that Helicobacter Pylori is the most important risk factor for gastric cancer and the most controllable risk factor for gastric cancer prevention. Eradication of Helicobacter Pylori should be the primary preventive measure for gastric cancer. Therefore, the screening of Helicobacter pylori is of great significance for reducing the incidence and mortality of gastric cancer.

  It is understood that at present, clinical methods such as C13/C14 breath test, rapid urease test and fecal antigen test are mainly used to detect Helicobacter pylori. Kangwei Century has been deeply involved in the fields of nucleic acid preservation, extraction and raw material enzymes for decades, and integrated the upstream three core technologies to develop the first domestic Helicobacter pylori nucleic acid detection kit based on fecal samples. Compared with other types of Helicobacter pylori detection products, the extracted nucleic acid not only has the advantages of high sensitivity and strong specificity, but also can be used for the detection of corresponding virulence factor genes and multiple antibiotic resistance genes, which can provide a more accurate treatment plan for the eradication of Helicobacter pylori, improve the eradication rate of Helicobacter pylori and reduce the incidence of gastric cancer.

  According to Jost Sullivan’s statistics, the market scale of Helicobacter pylori screening will be about 12 billion yuan in 2020. In the future, with the continuous improvement of public health management awareness and the listing of new technologies and new products such as Helicobacter pylori fecal nucleic acid detection kit, the penetration rate of Helicobacter pylori screening is expected to continue to increase, and the market scale of Helicobacter pylori screening will continue to grow.

  The company believes that this Helicobacter pylori nucleic acid detection kit not only helps to enhance the competitiveness of Kangwei Century in the related fields of early screening of gastric cancer, but also has positive clinical value and social significance for early screening, early diagnosis and early treatment of gastric cancer in China. Wang Chunxiang, chairman of the company, said that Kangwei Century will take promoting the development of life science as its mission, and become an industry leader in the field of biotechnology through continuous technological innovation, so as to make every life healthy and promising.

  Adjust the listing place Sany Heavy Industry plans to issue GDR and list it on Frankfurt Stock Exchange.

  () Announcement, the company intends to issue Global Depositary Receipts ("GDR") and apply for listing on Frankfurt Stock Exchange, Germany. The newly issued RMB common stock (A shares) ("A shares") is used as the basic securities of GDR. The newly-added basic securities A shares represented by GDR issued by the Company this time shall not exceed 425 million shares (including the securities issued due to the exercise of any over-allotment option, if any), and shall not exceed 5% of the total share capital of the Company’s common stock before this issuance.

  On March 16, 2022, the company disclosed its intention to issue global depositary receipts overseas and list them on the Swiss Stock Exchange. Based on the strategy of digital intelligence and the consideration of overseas industrial layout, the company plans to adjust the listing place of GDR to Germany. The company actively promotes the strategy of digital intelligence and is committed to becoming a global benchmark for intelligent manufacturing. Germany is the first in the world to launch Industry 4.0, with a number of advanced manufacturing enterprises in the world, and is at the global leading level in intelligent manufacturing. In addition, in 2012, the company acquired Putzmeister Company, a well-known global concrete equipment company, and established the largest overseas R&D and manufacturing base in Germany, which is a global construction machinery manufacturing town and one of the most important overseas markets of the company.

  Jewater’s listing price today is 38.26 yuan/share.

  According to the announcement of the exchange, Jewater is listed in science and technology innovation board of Shanghai Stock Exchange today. The company’s stock code is 688141, the issue price is 38.26 yuan/share, and the issue price-earnings ratio is 125.6 times.

  Micro-nano is listed today at a price of 24.21 yuan/share.

  According to the announcement of the exchange, Micronano is listed in science and technology innovation board of Shanghai Stock Exchange today. The company’s stock code is 688147, the issue price is 24.21 yuan/share, and the issue price-earnings ratio is 412.24 times.

A number of well-known pharmaceutical companies have been sold (attached list)

▍ Source: Announcement of Pharmaceutical Companies

▍ Finishing: Cypress Blue-Corn

▍ Industry concentration has been further improved.

In 2019, there were frequent mergers and acquisitions between pharmaceutical companies. Observing these cases, we can find that some of them spun off their subsidiaries and some strengthened their own strengths through acquisitions. In addition, the sale of non-core assets by foreign pharmaceutical companies and the takeover by domestic pharmaceutical companies have also caused industry analysis.

In these cases, some of them have been completed and some are still in progress. Through the inventory of one-year acquisition cases, it seems that the industry is progressing in the direction of increasing concentration.

With the deepening of medical reform, the implementation of policies such as consistency evaluation, quantity procurement and DRG, and the improvement of industry access threshold, SMEs will be acquired more frequently by large enterprises.

Of course, this is just like the plan of "supporting the merger and reorganization of pharmaceutical production enterprises, cultivating a number of large enterprise groups with international competitiveness, and improving the concentration of pharmaceutical industry" in the "Several Opinions on Further Reforming and Improving the Policy of Drug Production, Circulation and Use" issued by the State Council in early 2017.

Suzhou Novartis completed the sale.

On December 21st, Zhejiang Jiuzhou Pharmaceutical Co., Ltd. issued the Announcement on Completion of 100% Equity Delivery of Suzhou Novartis Pharmaceutical Technology Co., Ltd., and formally merged Suzhou Novartis into its subsidiary.

Jiuzhou Pharmaceutical announced on November 30 that the board of directors passed the Proposal on Foreign Investment to Buy 100% Equity of Suzhou Novartis Pharmaceutical Technology Co., Ltd., and estimated to buy 100% equity of Suzhou Novartis held by Novartis Investment with self-raised funds of about 790 million yuan.

According to the data, Suzhou Novartis acquired by Jiuzhou Pharmaceutical Co., Ltd. mainly consists of factory buildings, production lines, process equipment, etc. after divesting the technology and drug development assets held by Novartis.

Fosun Pharma sells assets for 3.6 billion yuan

On December 19th, Shanghai Fosun Pharma (Group) Co., Ltd. issued the Announcement on the Progress of Selling Assets and Foreign Investment, intending to transfer all the limited partnership interests of Healthy Harmony Holdings, L.P. (whose main assets are "United Family" hospitals and clinics) and the management partner of Healthy Harmony Holdings, L.P.. The consideration for this transfer is about US$ 523.15 million (equivalent to about RMB 3.6 billion).

Tasly sells Tasly Medicine Marketing Group.

On December 17th, Tasly announced that it had signed the Framework Agreement with Chongqing Pharmaceutical, and made an agreement on selling the equity of its holding subsidiary Tianjin Tasly Pharmaceutical Marketing Group.

According to the Framework Agreement, Chongqing Pharmaceutical intends to acquire 87.47% of the shares directly and indirectly held by the company and the shares held by other shareholders of Tianshi Marketing by paying cash consideration.

Nanjing pharmaceutical holding enhua herun

On December 13th, Nanjing Pharmaceutical Co., Ltd. issued the Announcement on Completion of Change Registration Procedures for Acquisition of Equity, indicating that the acquisition of Jiangsu Enhua Herun Pharmaceutical Co., Ltd. for 72.24 million yuan has completed the change registration procedures for shareholders and legal representatives. So far, Nanjing Pharmaceutical directly holds 70% equity of Enhua Herun.

China Resources Sanjiu acquires Aonuo Pharmaceutical.

On November 27th, China Resources Sanjiu Pharmaceutical Co., Ltd. issued the Announcement on Acquisition of 100% Equity of Aonuo (China) Pharmaceutical Co., Ltd., and planned to acquire 100% equity of Aonuo (China) Pharmaceutical Co., Ltd. held by Yuheng Pharmaceutical for 1.42 billion yuan.

According to the announcement, the core products of Aonuo Pharmaceutical are calcium zinc gluconate oral solution, vitamin C chewable tablets and Shenzhi Dendrobium granules, and its "Aonuo" and "Jinxin Jinjiute" are well-known brands for children to supplement calcium. China Resources Sanjiu said that the acquisition can improve the category layout of self-diagnosis and treatment (CHC), which can be organically combined with the advantages of China Resources Sanjiu in consumer insight, brand operation and terminal coverage.

Pfizer merged with Mylan.

On November 12th, Mylan and Pfizer officially announced the name of the new company-Via Tris, which was formed by the merger of Mylan and Pfizer’s subsidiary Pfizer Puqiang.

The 2018 financial report shows that Pfizer’s global revenue is $12.5 billion, and the China market contributes $2.4 billion. Mylan is a multinational giant, with a global revenue of 11.434 billion US dollars in 2018, and has not yet started business in China.

Da Shen Lin bought 123 chain pharmacies.

On November 7, Dashenlin Pharmaceutical Group Co., Ltd. issued the Announcement on Acquisition of 51% Equity of Nantong Jianghai Pharmacy Chain Co., Ltd., and plans to acquire 51% equity of Nantong Jianghai Pharmacy Chain Co., Ltd., with the target company including 123 chain pharmacies and the acquisition amount of 120 million yuan.

GSK sells Suzhou factory and Hepudin.

On July 8, Fosun Pharma announced that its holding subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., intends to acquire 100% equity of GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd. for no more than RMB 250 million. If the transfer is completed, it will hold the drug registration approval of lamivudine tablets (specification: 0.1g) for the treatment of chronic hepatitis B and the production license and GMP certificate of its production facilities.

On July 9th, GSK China confirmed to Cyberland that both parties expected the transaction to be completed by the end of November.

Sinopharm Holdings acquired Anhui Pharmaceutical Group

On May 8, the official public platform of Sinopharm Holding Anhui Co., Ltd. released a message: Sinopharm Holdings officially signed a contract to acquire Anhui Pharmaceutical Group. According to public information, Anhui Pharmaceutical Group is a large-scale commercial circulation enterprise approved by the Anhui provincial government in December 2002.

China Resources Medicine Acquires Jiangzhong

On April 17, Jiangzhong Pharmaceutical Co., Ltd. announced that the company recently received a notice from the controlling shareholder of the company. With the approval of Jiangxi Provincial Market Supervision Administration, the controlling shareholder completed the industrial and commercial change registration of the enterprise name and business scope on April 8, 2019.

After the change, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. was changed to China Resources Jiangzhong Pharmaceutical Group Co., Ltd. Jiangzhong Pharmaceutical said in its 2018 annual report that the brand value of "Jiangzhong" was 20.715 billion yuan, ranking 231st among the top 500 Chinese brands and 6th in the pharmaceutical industry. For China Resources Medicine, the acquisition of Jiangzhong Group won brands such as "Jiangzhong" and "Chuyuan".

Bristol-Myers Squibb acquires Xinji.

On January 3rd, Bristol-Myers Squibb announced a $74 billion acquisition of Xinji. According to the agreement between the two parties, Bristol-Myers Squibb will acquire Xinji Company in the form of $74 billion in cash and stock transactions to build a first-class biopharmaceutical giant that can compete with the world’s largest pharmaceutical manufacturer.

In fact, the merger and acquisition of pharmaceutical companies in 2019 is far more than that. By combing the actions of well-known enterprises, the purpose is to find the trend of industry changes under these mergers and acquisitions. In addition, in the announcements of many listed pharmaceutical companies selling assets this year, many properties were thrown out. Some analysts believe that pharmaceutical companies sell houses to survive, but a more rational view should be due to the limited value-added space of real estate.

1% to 10%, break through! Aiming at overseas "track" enterprises to usher in new business opportunities and new development

  CCTV News:At the beginning of 2024, in Zhejiang, a major foreign trade province, many enterprises have embarked on a new journey of "going out to sea" to grab orders. Not long ago, Zhejiang released the foreign trade data of the whole province in 2023. In 2023, the total import and export volume of Zhejiang reached 4.90 trillion yuan, a year-on-year increase of 4.6%. Among them, the export was 3.57 trillion yuan, an increase of 3.9%; Imports reached 1.33 trillion yuan, up 6.7%.

  Zhejiang Province proposes that it will do everything possible to stabilize foreign trade and optimize foreign investment, continue to lay a good combination of "stabilizing expansion and adjustment", further promote the action of "thousands of enterprises expand the market to increase orders", and cultivate new foreign trade formats and models such as overseas warehouses and digital trade to ensure that the share of exports in the country is basically stable. In the new year, Zhejiang government and enterprises joined forces to seize the start, laying a solid foundation for new achievements in foreign trade in the new year.

  In the past 10 years, the company has seized the opportunity of the rapid growth of textile and garment industry in the countries that jointly built the "Belt and Road", done a good job in market segmentation according to the market characteristics of the countries that jointly built the "Belt and Road", and established extensive cooperative relations with customers in the countries that jointly built the "Belt and Road".

  Just over 8,000 kilometers away in the China-Egypt TEDA Suez Economic and Trade Cooperation Zone, the first overseas factory of Caidie’s "Belt and Road" countries has officially laid the foundation stone. Compared with Butterfly, China Jushi, located in Tongxiang, Zhejiang Province, has taken the lead in setting up factories overseas in the Belt and Road Initiative.

  In 2012, China Jushi set up a factory in Egypt. In 10 years, Jushi Egypt’s glass fiber production capacity jumped from 80,000 tons to 340,000 tons. The rich local mineral resources and human resources have been effectively utilized, which directly promoted local development and directly created more than 2,000 local jobs.

  Enterprises are in action and the government is not idle. In 2024, Zhejiang Province will launch a new round of "thousands of enterprises" to expand the market and increase orders. In the first quarter, the province planned to organize 385 delegations, and planned to organize more than 4,000 enterprises with more than 6,000 people, including 128 delegations in January, with more than 1,500 enterprises planned. In 2024, we will strive to organize more than 1,000 delegations and more than 10,000 enterprises in the province to expand overseas and support more than 100 provincial-level key exhibitions.

  In 2023, Zhejiang’s foreign trade withstood multiple pressures such as sluggish external demand and falling prices, and its import, export and import all achieved positive growth. The bright data also shows that the diversified expansion of Zhejiang enterprises in the trade market is effective, and emerging markets are gradually becoming mature markets.

  According to statistics, in 2023, Zhejiang imported and exported 2.55 trillion yuan to countries that jointly built the "Belt and Road", an increase of 8.2%, accounting for 52.1% of the province’s total import and export value, and contributing 89.5% to the province’s import and export growth.

  The "second generation of factory" has undergone drastic transformation and upgrading, and foreign trade has made new development.

  As a big province of private economy, Zhejiang’s "private foreign trade" has distinct characteristics. The data shows that Zhejiang private enterprises continue to play the role of "ballast stone" in stabilizing foreign trade. In 2023, the number of private enterprises with import and export performance in Zhejiang exceeded 100,000 for the first time, reaching 102,000, and the total import and export accounted for more than 80% of the province’s foreign trade for the first time, driving the province’s foreign trade growth rate by 5.6 percentage points.

  Behind the development of private foreign trade, the reporter found that from the early days of reform and opening up, private enterprises developed and expanded, and the older generation of factory directors seized the opportunity to save their family business to the period of transformation of old and new kinetic energy. A group of "post-80 s" and "post-90 s" young people took over the baton of their parents and became the "second generation of factories". Facing the current complicated foreign trade situation and the new environment of traditional manufacturing industry, how did they break through the trend?

  Ke Qiao, Shaoxing, Zhejiang is the largest textile trade distribution center in the world. With the change of economic environment, the cost of labor and raw materials has risen sharply, but the order volume has dropped sharply.

  Shao Lingbin, the second generation of the factory, took over the enterprise in 2016. When it first took over, the enterprise still followed the traditional way of foreign trade development, relying on the mode of "receiving orders and producing" to make profits. However, with the intensification of product homogenization competition and the dilution of profits, the factory has fallen into a dilemma of development. As a last resort, Shao Lingbin began a drastic road of transformation.

  Shao Lingbin aims to be the top-notch in the industry, investing 10 million yuan in research and development expenses every year, setting up a special team and hiring high-end designers from all over the world with high salaries. After more than three years of research and development, the enterprise finally broke the technical monopoly of foreign enterprises on acetic acid fabrics, and became the national development base of acetic acid and polyester fashion fabrics in one fell swoop, successfully filling the gap in the domestic market.

  Yang Wei is a "post-80s" and a "second generation factory". At the beginning of the new year, the smart factory built by the enterprise with an investment of 150 million yuan has been partially put into production. During this time, he is busy purchasing equipment and checking the production line.

  In fact, when he first planned to do intelligent transformation, Yang Wei also encountered many voices of doubt.

  Yang Wei told reporters that after intelligent transformation, the production capacity of enterprises has increased by 50% and the production efficiency has increased by 30%.

  Breakthrough of 1% to 10% The number of cross-border online stores in Zhejiang has increased by 20,000 annually.

  With the rapid development of globalization and Internet technology, cross-border e-commerce has become a new kinetic energy for foreign trade development. At present, there are 199,000 active export online stores in Zhejiang Province, with an increase of 23,000 in 2023. The proportion of cross-border e-commerce goods in foreign trade has also increased from less than 1% in 2015 to nearly 10% in 2023. From "1" to "10", cross-border e-commerce is bringing new business opportunities to thousands of enterprises in Qian Qian.

  In a scooter manufacturer in Yongkang, Zhejiang, workers are rushing to make a batch of orders sent to Europe before the Spring Festival. In 2024, they just switched from domestic sales to cross-border e-commerce, and have already completed millions of dollars in sales.

  A cross-border e-commerce "zero-based" enterprise like this can not achieve such results in a short time without the guidance and training of service companies. Ruan Xueqing is the team leader responsible for the operation of this enterprise’s cross-border e-commerce project. In 2024, one tenth of the projects they received were pure domestic trade enterprises transformed into cross-border e-commerce.

  Nowadays, there are more and more domestic trade enterprises aiming at overseas "track". However, due to the different standards and needs of the domestic and foreign markets, the problem of "acclimatization" will also occur when domestic and foreign trade turn to each other. In the R&D department of this fitness equipment enterprise in Hangzhou, technicians are testing an intelligent spinning bike, which will be sold simultaneously in the international and domestic markets.

  Since 2022, this enterprise has been "going out to sea" through cross-border e-commerce brands, and its export sales have doubled, which is almost the same as domestic sales. In a promotion activity of overseas e-commerce platform, one of their rowing machine products sold 4500 units in two days, equivalent to domestic sales for half a year.

  According to the data of Zhejiang Provincial Department of Commerce, in 2023, the import and export of cross-border e-commerce in the province was 512.93 billion yuan, an increase of 18.9% year-on-year. Among them, the export was 393.28 billion yuan, an increase of 24%.

Structural optimization, steady improvement and quality improvement, foreign trade has continuously reached a new level.

CCTV News:In the past ten years, China’s total trade in goods has been continuously improved, ranking first in the world for five consecutive years since 2017, and the total trade in goods and services has also jumped to the top in the world in 2020. While the high-quality development of trade has made historic achievements, the continuous improvement of China’s foreign trade has also played an important role in the development of the national economy and the recovery of the world economy.

At 3 o’clock in the morning, the stall of fruit distributor Zheng Yuqiang became lively. This evening, a new batch of imported jackfruit was welcomed.

Zheng Yuqiang, Beijing fruit distributor:We seldom sold jackfruit a few years ago. Now, if it is normal, it is no problem to sell (sell) more than ten tons a day.

In Beijing’s largest wholesale market for agricultural products — — In Xinfadi market, mid-October is not the peak season for fruit sales, and several imported fruits promoted by Zheng Yuqiang have increased his business.

Beijing fruit buyer Zheng Zhen:I bought some jackfruit and red pitaya today. I come here almost every day and sell everything. There are about 30 to 40 kinds of imported fruits.

In the wholesale market in Beijing, the varieties of imported fruits sold are increasing year by year. Xiao Yang, who just entered the business last year, opened a shop specializing in selling Malaysian Maoshanwang durian. He told reporters that this expensive imported fruit has been selling better and better since it entered the China market in 2019.

Xiao Yang, a distributor of imported fruits in Beijing:Sales are gradually increasing. At the beginning, the people still didn’t approve of it because the price was relatively high. Up to this year, the people’s recognition level is still relatively high, especially people like Beijing who buy more.

In the past ten years, more and more imported fruits such as Philippine avocado, Cambodian banana, Lao citrus and South African pear have entered the mouth of China people. In 2021, China imported more than 7 million tons of fruit, compared with less than 3.45 million tons in 2012, and the import volume doubled in ten years.

Zhang Xiao, Director of the Inspection and Quarantine Department of Animals and Plants and Food of Nanning Customs:At present, the imported fruit varieties from ASEAN have increased from 53 varieties in six countries ten years ago to 77 varieties in the whole ASEAN countries.

Not only high-quality consumer goods such as fruit, but also the import scale of advanced technology and equipment, key parts and other products has been expanding over the past decade, which has better met the needs of domestic production and people’s lives, and also allowed the world to share more dividends brought by China’s economic growth. In 2021, China’s total import value reached 17.37 trillion yuan, an increase of 51.2% compared with 2012.

Professor Cui Fan, School of International Business and Economics, University of International Business and Economics:The country’s opening up, especially (import), includes high-quality products that are beneficial to people’s living standards and meet people’s needs, so that our trading partners can share the fruits of China’s economic development.

In the past ten years, China has taken the initiative to reduce commodity tariffs, and the total tariff level has dropped from 9.8% in 2012 to 7.4% in 2021. New trade formats and new kinetic energy are constantly being stimulated, and the import and export scale of cross-border e-commerce has increased nearly tenfold in the past five years.

High-level import and export will further optimize the trade structure. In a factory in Qingdao, Shandong Province, 10 sets of high-speed EMUs for Jakarta-Bandung High-speed Railway have been manufactured and are waiting for delivery. Last month, the first batch of Jakarta-Bandung High-speed Railway high-speed EMUs and comprehensive inspection trains exported to Indonesia arrived in Jakarta Port smoothly, which was the first time that China’s high-speed trains were exported abroad.

Zhang Fangtao, Chief Designer of Jakarta-Bandung High-speed Railway High-speed EMU:The Jakarta-Bandung High-speed Railway high-speed EMU will be sent to Indonesia in November, and Jakarta-Bandung High-speed Railway will be put into operation in 2023 according to the plan. By then, the travel time from Jakarta to Bandung will be shortened from the current three hours to about 40 minutes.

Going out with high-end equipment, there are our supporting services. In the past ten years, the leading export industries have been transformed and upgraded from traditional labor-intensive products to high-tech industries, and the knowledge-intensive service trade has maintained rapid growth.

Ma Qiang, Deputy General Manager of overseas business department of CRRC Sifang Co., Ltd.:We provide maintenance technical support for Argentine national railway company. Up to now, the company’s products and services have been exported to 29 countries and regions around the world.

From 24.4 trillion yuan in 2012 to 39.1 trillion yuan in 2021, in the past ten years, China’s total trade in goods has continued to increase, and its international market share has also increased from 10.4% in 2012 to 13.5% last year, and its position as the largest country in global trade in goods has been further consolidated. Nowadays, there are more and more high-level platforms for opening to the outside world, such as China China International Import Expo(CIIE), Service Trade Fair and Consumer Expo. China has set up 21 free trade zones and one free trade port, with free trade partners spread across five continents. In the past ten years, China’s average contribution rate to world economic growth reached 38.6%, ranking first in the world.

Russian troops control the capital of South Ossetia.

  At least 1,500 people were killed in the conflict, and Saakashvili said that Russia and Georgia entered a state of war.



In South Ossetia, a Georgian tank was hit and burst into flames. This edition of photos was issued by Xinhua News Agency.



On the 9th, Georgia declared a "state of war".



Georgian soldiers ran past a building that caught fire after being attacked.


  The conflict in South Ossetia, Georgia escalated on the 9th. The Russian military announced on the same day that it had taken control of Tskhinvali, which Georgia claimed to control the day before. Georgia declared a "state of war" on the 9th. Georgian President Saakashvili said that Russia "invaded Georgia without scruple". Although the two countries did not declare war, they actually entered a state of war.


  At least 1,500 people have died in South Ossetia as of the 9th, and more than 30,000 refugees have flooded into Russia. US President Bush called for a ceasefire between the two sides.


  situation on the battlefield


  Russian troops killed and injured more than 100 people.


  The conflict in South Ossetia, Georgia, continued on the 9th. Russian peacekeepers who entered South Ossetia took control of Tskhinvali that day. The Georgian side has not confirmed this statement. Anatoly Nagovitsyn, Deputy Chief of Staff of the Russian Armed Forces, said on the 9th that two Russian warplanes were shot down.


  This is the first time that Russia has admitted that the fighter plane was shot down. Georgia claimed on the same day that it shot down 10 Russian warplanes and destroyed 30 tanks.


  Igor Konashenkov, Assistant Commander-in-Chief of the Russian Army, said that the number of peacekeepers killed in Russia rose to 15 on the 9th, and 150 were injured. It is unclear how many soldiers and equipment the two sides have invested.


  respond


  Ge recalled troops in Iraq


  Georgian President mikhail saakashvili said on the 9th: "I signed a decree declaring the country into a state of war". Alexander Lomaya, secretary of Georgia’s National Security Council, later said that the Georgian parliament unanimously passed the order signed by Saakashvili on the same day, announcing that the country had entered a state of martial law for 15 days.


  On the 9th, the Georgian government evacuated the staff in the Presidential Palace and other office buildings to guard against air strikes by Russian warplanes.


  Bondo Maisuradze, commander of Georgian troops in Iraq, said on the 9th that Georgia plans to withdraw all its troops in Iraq and transfer them all to South Ossetia.


  Maisuradze said: "All Georgian troops (in Iraq) should leave." He said that the specific withdrawal plan has not yet been finalized, and Georgia has asked the United States for assistance. Earlier, Saakashvili said in an interview with the media that he began to withdraw troops stationed in Iraq on the 9 th. There are 2000 Georgian troops in Iraq.


  progress


  Russia wants to send more troops to promote peace


  Russian President Dmitry Medvedev convened Defense Minister Anatoly serdyukov and Armed Forces Chief of Staff Nikolai makarov to discuss the situation in South Ossetia on the 9th. Medvedev said: "Russian peacekeepers and reinforcements are now taking action to force Georgia to (agree to restore) peace." Russian Foreign Minister Sergei Lavrov said that "the situation in South Ossetia continues to deteriorate" and has now suffered a "humanitarian disaster". He said that about 1,500 people in South Ossetia died in the conflict, and the death toll continues to rise.


  Itar-Tass quoted sergey sobyanin, director of the Russian Prime Minister’s Office, as saying: "More than 30,000 refugees have poured into Russia in the past 36 hours."


  ■ Link


  China calls on all parties to the conflict to cease fire.


  China’s Foreign Ministry spokesman Qin Gang said on the 9th that China is seriously concerned about the escalation of tension and armed conflict in South Ossetia. China calls on relevant parties to exercise restraint and cease fire immediately. Qin Gang said: We sincerely hope that all parties to the conflict can resolve their disputes peacefully through dialogue, so as to maintain peace and stability in the region.


  US President Bush, who is in Beijing, said on the evening of 9th that the armed conflict in South Ossetia has affected the peace of the whole region. He called on all parties to cease fire immediately and return to the position before August 6.


  The United Nations Security Council met on the 8th to discuss the conflict in South Ossetia, but the 15 members failed to reach an agreement. This is the second meeting of the Security Council in the past two days to discuss this issue.


  analyse


  The United States and Russia wrestle over South Ossetia.


  Georgian President Saakashvili has been pursuing the policy of actively integrating into the West and joining NATO since he took office. This policy is strongly supported by the United States.


  After Kosovo declared independence in February this year, Russia began to adjust its policy toward South Ossetia in order to counter the US position of recognizing Kosovo’s independence. On March 21, the Russian State Duma adopted a statement suggesting that the Russian President and government consider recognizing the independence of South Ossetia. Subsequently, then Russian President Vladimir Putin ordered relevant Russian parties to provide material assistance to residents of South Ossetia and Russian expatriates, and to establish a local mechanism to comprehensively protect the rights and freedoms of Russian expatriates.


  In view of this situation, Georgia resolutely opposes it on the one hand, and actively seeks international support, especially the support of the United States on the other. The Georgian army has also strengthened construction, equipped with new weapons, received training from American instructors, and conducted joint military exercises with the United States and other countries.


  Analysts believe that the independence of South Ossetia is a major obstacle for Georgia to join NATO, and Georgia launched such a large-scale military operation to eliminate this obstacle. Russia will never allow Georgia’s central government to fully control this region.


  Analysts believe that the United States and Russia are two key supporters of Georgia and South Ossetia respectively. The policies of the United States and Russia will affect the trend of the situation in South Ossetia.


  Special text According to Xinhua News Agency


  ■ background


  South Ossetia has a long history.


  South Ossetia, located in the Caucasus, is an autonomous prefecture of Georgia, bordering Russia’s North Ossetia, with an area of 3,900 square kilometers and 70,000 residents. South Ossetia demanded independence in the early 1990s, and there were many armed conflicts with the Georgian central government.


  Since 1992, Russia, Georgia, South Ossetia and North Ossetia have formed the Quadripartite Mixed Supervisory Committee to resolve the conflict in South Ossetia, and the former three parties have formed a mixed peacekeeping force to station in the conflict area.


  After taking office in early 2004, Georgian President Saakashvili promised to restore Georgia’s control over the entire South Ossetia region.


  In November 2006, the second referendum in South Ossetia passed the demand for independence, but it was not recognized by the central government.


  On August 7, 2008, Saakashvili announced a ceasefire and called on the South Ossetian authorities to cease fire immediately and respond to the proposal of direct negotiations. South Ossetia said it agreed to a temporary ceasefire.

Editor: Zhang Renhe

People who die suddenly have these rules.

You may think that you are in good health and there will be no major problems, but you know what? Some people suddenly fell down and never woke up because of temporary excitement or fatigue. This is sudden death, an unpredictable fatal event.

There seems to be nothing wrong. Why did you die suddenly?

Is there any rule of sudden death? Is there any warning? Can we avoid it? To answer these questions, let’s take a look at a recent study.

This study was published in the journal chinese journal of critical care medicine in April, 2020, entitled "Analysis of Epidemiological Characteristics of 5,516 Cases of Autopsy Sudden Death in China". The researchers dissected the bodies of 5516 cases of sudden death and found the following important findings:

1. Emotional excitement and fatigue are the most common causes.

The study found that among the causes of sudden death, emotional excitement accounted for 26%, fatigue accounted for 25%, and blood volume change accounted for 8.95%. Other inducements include drinking, satiety and minor injuries.

2. Heart problem is the main reason.

It was found that among the causes of sudden death, cardiogenic sudden death accounted for 57.76%, pulmonary sudden death accounted for 21.63%, and brain-derived sudden death accounted for 9.21%. Sudden cardiac death is mainly caused by coronary heart disease, myocardial infarction and arrhythmia.

3. There are often some uncomfortable signals before sudden death.

It is found that people with symptoms and signs in sudden death are most often manifested as sudden attack (20.10%), rest and sleep (16.71%), followed by vomiting (7.49%), dyspnea, chest tightness and sweating, dizziness, chest pain, abdominal pain, convulsion, headache, palpitation, cough and disturbance of consciousness.

People with chronic diseases are more prone to sudden death.

It was found that hypertension (37.95%), heart disease (30.02%) and diabetes (23.79%) were the most common among those with past history. Followed by dysplasia, hyperlipidemia, tumor, infection, hyperthyroidism and so on.

5.30 ~ 63 years old is the high incidence age of sudden cardiac death.

People in this age group are at an important stage of their career and family, with high work pressure, fast pace of life, irregular diet, and addiction to cigarettes and good wine, which may easily lead to "three highs" and coronary heart disease.

How to avoid sudden death? Please do the following three points.

From these laws, we can get some enlightenment:

Middle-aged people should pay attention to controlling their emotions!

Do you often get angry and quarrel with others because of some small things? Are you sometimes so excited that you get carried away and even laugh until you cry? You may think these are normal emotional expressions, but you know what? These mood swings may bring fatal danger to your heart!

A media person once witnessed such a tragedy. Her father-in-law was taken to the hospital because of a sudden acute myocardial infarction, and survived after the rescue. However, she found that in her father-in-law’s ward, the other six patients have one thing in common: they are all quick-tempered and short-tempered, and they are emotional, angry and angry when things happen.

She learned a lesson from it: these people are all out of control because of their emotions, which leads to heart problems!

Why is emotional excitement harmful to the heart?

It turns out that when we are angry or excited, the body will secrete a lot of hormones such as adrenaline and cortisol, which will double the blood flow of the heart, strengthen the contractility of the heart and accelerate the heartbeat. At the same time, blood vessels will contract, blood pressure will increase and blood viscosity will increase. In this way, the heart will bear a greater burden, prone to arrhythmia, myocardial ischemia, chest tightness, palpitation and other symptoms. If the duration is too long or the frequency is too high, it may induce serious cardiovascular events such as angina pectoris or myocardial infarction.

Therefore, middle-aged people should learn to adjust their emotions and maintain peace. Don’t vent or suppress things that don’t go your way, but find a suitable way to release the pressure. For example, you can chat with friends, listen to music, do sports and read books. This can not only relax the body and mind, but also enhance the physical fitness, which is beneficial to the heart.

Middle-aged people should rest moderately and avoid overwork!

Are you often so busy with work and family that you even ignore your physical discomfort? You may think it’s your responsibility and responsibility, but you know what? This lifestyle may make your heart stop beating at any time!

Research shows that many sudden deaths have experienced high pressure, long-term and high-intensity working conditions. This kind of work will make your sympathetic nerves overexcited, leading to heart overload, arrhythmia and myocardial ischemia. If the duration is too long or the frequency is too high, it may lead to fatal cardiovascular events such as arrhythmia or myocardial infarction. Some people die suddenly because of working overtime overnight, mood swings and nervous stress, which leads to neurological dysfunction, coronary artery spasm and sudden stop of blood supply to the heart.

Therefore, middle-aged people should arrange their work and rest reasonably, don’t be overworked, and don’t stay up late to hurt themselves. It is necessary to do some aerobic exercise properly to relax and enhance physical fitness. It is necessary to have a regular physical examination to find and treat chronic diseases in time. Keep good living habits and stay away from alcohol, tobacco and greasy food. Only in this way can you protect your heart from the threat of sudden death.

Middle-aged people should pay attention to body signals and seek medical treatment in time!

You may not know that before sudden death, your body actually gave you many warnings. If you can find and deal with it in time, it is possible to avoid the tragedy.

So, what are the signals before sudden death? According to research, the most common symptom before sudden death is chest discomfort, which mainly has the following three manifestations:

Angina pectoris. This is a feeling of pain or oppression in the chest or precordial area, which usually lasts less than 15 minutes and is often accompanied by dysphagia or chest tightness. This is caused by heart ischemia and hypoxia.

Flustered. This is a feeling of rapid or irregular heartbeat, which usually lasts less than 10 minutes and is often accompanied by discomfort such as chest tightness, fatigue and dizziness. This is due to cardiac electrophysiological dysfunction.

Low blood pressure. This is a state in which blood pressure drops below the normal value, which generally lasts less than 5 minutes, and is often accompanied by symptoms such as cold sweat and dyspnea. This is because the pumping function of the heart is weakened.

These signals mostly occur after physical activity, emotional excitement or satiety. If they can be relieved after rest, it means a mild heart problem. However, if it still doesn’t improve after rest, or there are frequent or persistent signals, it means that it is a serious heart problem and needs immediate medical attention.

In addition to these signals, there are some less obvious signals, such as left arm pain, sore throat or toothache. These signals may be nerve reflexes caused by heart problems, which also need attention.

In short, middle-aged people should pay special attention to their physical changes. If there is any chest discomfort, dull pain or fatigue, they should go to the hospital for examination in time and don’t take it lightly. Only early detection and treatment of heart problems can effectively prevent and reduce the risk of sudden death.

Paper materials: Analysis of Epidemiological Characteristics of 5516 Cases of Autopsy Sudden Death in China, chinese journal of critical care medicine Journal in April 2020.

Original title: "Doctors dissected more than 5,000 cases of sudden death and found that people who died suddenly had these rules! 》

Read the original text

Notice of Beijing Municipal Health Insurance Bureau on Further Improving the Direct Settlement of Medical Treatment in Different Provinces of Basic Medical Insurance

Beijing Medical Insurance No.41 [2022].

The medical insurance bureaus of all districts, the Social Affairs Bureau of Beijing Economic and Technological Development Zone, and the designated medical institutions:

  In order to continuously improve people’s sense of gain, happiness and security in medical treatment settlement in different places, according to the spirit of the Notice of the National Medical Insurance Bureau and the Ministry of Finance on Further Improving the Direct Settlement of Medical Treatment in Different Provinces of Basic Medical Insurance (No.22 [2022] of Medical Insurance), this Municipality further improves the direct settlement of medical treatment in different provinces of basic medical insurance (hereinafter referred to as direct settlement) and regulates the management of direct settlement services. The relevant matters are hereby notified as follows:

  First, improve the direct settlement policy

  (a) unified hospitalization, general outpatient and outpatient chronic diseases direct settlement fund payment policy. The medical expenses for inpatient, general outpatient and outpatient chronic and special diseases directly settled by the insured shall, in principle, implement the payment scope and relevant regulations (payment scope of basic medical insurance drugs, medical service items and medical consumables) stipulated by the insured place, and implement the relevant policies such as the basic medical insurance fund Qifubiaozhun, payment ratio, maximum payment limit and outpatient chronic and special diseases.

  (two) to clarify the scope of medical records in different provinces. Insured persons in this city can apply for inter-provincial medical record when they need medical treatment in different places. After the record, the insured persons can enjoy direct settlement service in the inter-provincial networked designated medical institutions where medical treatment is filed.

  (3) Standardizing the validity period of inter-provincial medical records in different places. Insured persons in this Municipality may, when filing medical treatment in different places across provinces, choose their own effective period of filing according to actual needs, and the effective date and deadline of filing shall be subject to the date of system registration. When the insured person’s place of filing for medical treatment or unit, insurance type and other insured relationships change, it is necessary to go through the filing procedures again, and the original filing validity period will automatically expire after re-filing.

  (4) It is allowed to re-submit medical records in different provinces and places, and the injured insured without third-party liability can enjoy direct settlement services. Before the settlement of the insured’s inter-provincial medical treatment in different places, the inter-provincial networked designated medical institutions shall provide direct settlement services for the insured. If the insured person who goes to different provinces for medical treatment goes through the filing formalities according to the regulations after being discharged from hospital at his own expense, he can apply for manual reimbursement of medical insurance according to the regulations of the insured place. At the same time, the medical expenses of trauma without third-party liability that meet the management regulations of medical treatment places can be included in the direct settlement scope.

  Two, standardize the direct settlement management services

  (a) simplify the inter provincial medical record. Insured persons in this city need to go through the inter-provincial medical record before seeking medical treatment in different places. The filing procedures can be handled through online and offline channels, such as the national medical insurance service platform APP, the national remote medical filing applet, the the State Council client applet or the window of each district agency, by registering my information and signing a personal commitment letter.

  (two) clear the scope of direct settlement. When the insured persons in this city apply for medical treatment in different provinces for the record, in principle, the medical treatment place only needs to be put on record in the co-ordination area where the medical treatment place is located. All the inter-provincial networked designated medical institutions in the co-ordination area for the record medical treatment are designated medical institutions for the insured persons in different places, and they can enjoy hospitalization, general outpatient service or direct settlement service for drug purchase. The insured persons in this city who seek medical treatment for special diseases in different provinces need to be filed with the designated medical institutions at the place where they seek medical treatment. In principle, two designated medical institutions can be selected for a special disease, and they can seek medical treatment in the inter-provincial networked designated medical institutions that have opened the direct settlement service for corresponding outpatient chronic and special diseases, and the treatment expenses related to special diseases can enjoy direct settlement service.

  (three) standardize the insured to medical insurance electronic certificate, social security card. Insured persons who seek medical treatment in different places across provinces should take the initiative to show their insured status in the designated medical institutions networked across provinces where they seek medical treatment, and produce valid certificates such as medical insurance electronic certificate or social security cards. Inter-provincial networking designated medical institutions should do a good job in the authentication of insured persons in different places, guide those who have not filed for the record to go through the filing procedures in time, and provide reasonable and standardized diagnosis and treatment services and convenient and fast settlement services for insured persons who meet the requirements of medical places.

  (4) Standardize the direct settlement process. When medical treatment is directly settled in different provinces, the medical treatment place should upload the cost information to the national medical security information platform according to the unified requirements of the state for direct settlement between designated medical institutions and insured persons connected across provinces. If it cannot be settled directly for some reason, the inter-provincial networked designated medical institutions should also upload medical expenses details, diagnosis and other medical information, and support the pilot online processing of manual reimbursement.

  (five) the unified management of medical treatment. Medical insurance agencies at all levels should bring medical personnel from different places into the unified management of this Municipality, and provide the same services and management as the insured in this Municipality in terms of medical information recording, performance appraisal, medical behavior monitoring, cost audit, total budget, etc., and make it clear in the medical security service agreement of designated medical institutions; Explore the application of medical insurance payment reform in medical settlement in different places, and guide designated medical institutions to make reasonable diagnosis and treatment.

  (six) to strengthen the collaborative management of medical services across provinces. Medical insurance departments at all levels should gradually improve the working mechanism, form a coordinated management system of inter-provincial medical services in different places with clear division of labor, clear responsibilities and unified processes, and comprehensively improve the coordinated management ability of inter-provincial medical services in terms of problem coordination, online reimbursement, cost investigation and information sharing.

  Three, strengthen the management of medical funds across provinces and different places.

  The medical insurance fund payment part of the inter-provincial medical expenses in different places shall be paid in advance and then liquidated. Inter-provincial medical expenses in different places shall be settled in full on a monthly basis in accordance with the unified national clearing method. The municipal medical insurance agency and the municipal finance department shall, in accordance with the detailed rules for the implementation of direct settlement of medical treatment in different provinces of Beijing (Annex), coordinate in the allocation and collection of clearing funds. Bank charges and bank bill fees incurred in the process of allocating funds for medical treatment in different provinces shall not be charged in the fund. The interest generated by the advance payment in the financial special account of the medical treatment place belongs to the medical treatment place.

  Fourth, improve the support for standardization of medical insurance informationization

  (a) continue to deepen the national unified medical insurance information platform for the whole business process application. Medical insurance departments at all levels should solidly promote the dynamic maintenance and deepening application of coding in accordance with the unified national norms and requirements, improve the management system of medical insurance operation and maintenance of information technology, continuously improve the level of medical insurance data governance, and provide strong system support for direct settlement.

  (2) Continue to optimize and improve the system. Medical insurance departments at all levels should constantly optimize system performance, reduce response time and effectively improve the direct settlement experience of insured persons in accordance with the unified national interface standards and specifications. When the medical insurance system stops and switches, it should be reported in advance, verified in the process and monitored afterwards to ensure that the data migration is timely, complete and accurate, to solve the influence of information changes such as personal number on the business in transit, and to ensure the smooth connection of business and the stable operation of the system.

  (3) Strengthen system operation and maintenance management and security. Medical insurance departments at all levels should continue to build professional and reliable operation and maintenance management teams, build operation and maintenance management processes in infrastructure, network security, cloud platforms, business subsystems and other fields, and form a scientific and effective operation and maintenance management system. Implement safety management responsibilities, improve system safety operation and maintenance capabilities, strengthen information system boundary protection, prohibit cross-provincial networked designated medical institutions from connecting the information system of medical insurance system to the Internet, standardize cross-provincial medical identity verification, and ensure data security. Standardize the quality control standard of abnormal transaction error information, classify the problems, describe the reasons of errors concisely and easily, facilitate the problem location of abnormal transactions, and respond to them in time.

  Five, strengthen the supervision of direct settlement funds

  Medical insurance departments at all levels should earnestly implement the regulatory responsibilities of medical treatment places and insured places. As a place for medical treatment, direct settlement should be regarded as the key content of daily supervision, special inspection and flight inspection, and all kinds of fraudulent insurance fraud should be severely cracked down. At the same time, it is necessary to cooperate with medical insurance departments in different places to do relevant verification; As an insured place, it is necessary to regularly analyze the use of medical insurance funds across provinces and different places, accurately lock the clues of suspicious problems, and actively carry out problem verification to ensure the safe and rational use of medical insurance funds.

  Medical insurance departments at all levels shall, in accordance with the spirit of this circular, take direct settlement as an important task to deepen the reform of the medical security system, strengthen organizational leadership, coordinate and promote, and do a good job in publicity and training to ensure a smooth transition of direct settlement in this Municipality.

  This notice shall be implemented as of January 1, 2023. If the previous documents are inconsistent with this notice, this notice shall prevail.

Beijing Municipal Medical Security Bureau    

December 30, 2022  

Learn the daily question and answer of the Decision | Why should we promote the coordinated development and governance of medical care, medical insurance and medicine?

Xinhua News Agency, Beijing, October 23 rd, the Central Committee of the Communist Party of China’s Decision on Further Deepening Reform and Promoting Chinese Modernization pointed out: "Promote the coordinated development and governance of medical care, medical insurance and medicine." Medical treatment refers to the medical and health services provided by medical and health institutions and medical personnel. It is the core content of medical treatment, health care and rehabilitation for the masses. It has the most direct relationship with the masses and the most concrete feelings of the masses. Medical insurance refers to the medical security system and its level of protection. Medical insurance fund is the "life-saving money" for people to see a doctor, and it is also an important source of financing for medical services and medical products. Medicine refers to Chinese and western medicines, medical devices, medical consumables and other related products. As an important means of medical and health services, it is directly related to the quality, safety and ability of services. The state exercises strict supervision over medical products to ensure quality, safety and effectiveness, and encourages innovation to increase the supply of high-quality medical products. There are three main considerations for the coordinated development and governance of "three medicines".

First, the "three doctors" are interrelated and inseparable. Medical care plays a major role in serving the people’s life, illness, illness, and medical treatment. By deepening the structural reform of the supply side of medical services, we will vigorously develop new quality productivity of health care, mobilize the enthusiasm, initiative and creativity of the majority of medical staff, promote the high-quality development of health care, and better meet the people’s yearning for a better life. Medical insurance is connected with the "demand side" of the people, which reduces the economic burden of patients by exerting the guarantee function; The other end is connected with the two "suppliers" of medical care and medicine, which can not only adjust the supply of medical services, standardize medical service behavior, promote hospital reform and promote graded diagnosis and treatment through payment methods and price policies, but also reduce the price of medical products through centralized procurement of pharmaceutical consumables and exert leverage. The production and supply of high-quality and high-efficiency pharmaceutical products provide necessary technical means and material guarantee for medical and health services, and at the same time get reasonable compensation from payers such as medical insurance to realize the healthy development of the industry. Medical care, medical insurance and medicine jointly protect people’s health. To improve the development level of health undertakings, it is necessary for relevant departments to cooperate closely and make concerted efforts to promote the coordinated development and governance of "three medicines".

Second, the coordinated development and governance of the "three medicines" can further benefit the people and the people and better solve the people’s livelihood problems. Medical and health service is an important part of public service and an important field that people expect for a better life. With the development of economy and society and the continuous improvement of people’s living standards, people hope to obtain more safe, effective, convenient and cheap medical and health services, more comprehensive coverage and higher level of basic medical security, and innovative and advanced medical products. Only by vigorously promoting the coordinated development and governance of the "three medicines" and forming a joint effort can we better meet the people’s new expectations for a better life, improve the people’s sense of acquisition, happiness and security, and deepen the reform of the medical and health system to benefit people’s livelihood more directly.

Third, the coordinated development and governance of the "three medicines" is conducive to promoting the governance of all links in the whole chain of the medical field and correcting unhealthy trends. Influenced by many factors, there are still some phenomena and problems in the field of medicine and health that endanger the interests of the people and harm public welfare and people’s health rights and interests. Among them, there are some problems in medical service, such as big prescription, excessive examination and overuse of drugs, which damage people’s health and waste health resources; There are also fraudulent behaviors in the field of medical insurance, which seriously threaten the safety of medical insurance funds; There are also problems in the field of pharmaceutical production, circulation and sales, such as "sales with gold", price increases at different levels, and imaginary costs. These problems are often intertwined, connecting multiple stakeholders and running through many links of "three medicines". To solve these problems, we must adhere to the party’s leadership, treat both the symptoms and the root causes, strengthen supervision in the whole chain, comprehensively adopt institutional supervision, functional supervision, behavioral supervision, penetrating supervision, continuous supervision and other means, strengthen the linkage between the "three medical" departments, strengthen the connection between discipline and law and execution, and severely crack down on and punish acts that infringe on public rights and interests according to law. The coordinated development and management of the "three medicines" can achieve the above objectives, and play a positive role in controlling unhealthy trends and establishing new trends in the industry, and play a significant role.

Is it not accidental that two Chinese people were arrested for bringing chameleons back to China?

       CCTV News:These days, a storm surrounding Madagascar chameleon has been fermenting. The cause of the incident should also start with a post from a Weibo netizen named @ Daiwa Exploring the World. On February 18th, the day before the Lunar New Year Lantern Festival, this Weibo netizen @ Daiwa explored the world and published an article entitled "Help my mother quickly". This article said that two China men, Wu Mou and Ma Moumou, organized and led a group of 19 parents and children to Madagascar for the New Year in February this year, and participated in outdoor activities such as parent-child popular science tours.

       According to the article, the so-called China men Wu Mou and Ma Moumou claimed to be "entomologists of China Academy of Sciences", but they led their children and parents to "teach children to catch wild animals with their bare hands" and even violated local laws during their travels in Madagascar, regardless of their lives. According to the article, when the group returned to China, they put a live chameleon in the bag of a child’s parents and tried to smuggle it back to China. As a result, the so-called "organizer" Ma Moumou and the parents were arrested by the Madagascar police at the airport, with a maximum of 10 years’ imprisonment and a high fine of up to 200 million Malagasy dollars (about 400,000 yuan).

one

       There are many questions to be solved about the private chameleon.

       At present, there are still many doubts about this incident. Are the "Wu Mou and Ma Moumou" mentioned in this net really the so-called "insect experts of China Academy of Sciences"? During the Chinese New Year this year, the 19-member scientific delegation led by them, including parents and children, traveled to Madagascar. Is it really qualified? The most controversial point is whether a China parent who was detained by the Malagasy police involved brought the chameleon back to China privately, or "Wu Mou and Ma Moumou", as mentioned in the article, secretly put the live chameleon in her backpack in an attempt to bring it back to China without the parents’ knowledge. Although these questions haven’t been clearly answered, official website, the Embassy of China in Madagascar, has released the relevant notice of this incident. At present, this incident of "China tourists being detained by Madagascar police on suspicion of taking prohibited items such as chameleons out of the country" is in the judicial review stage, and there is no specific court date.

       There is no specific court date under judicial review.

       China’s Embassy in the Republic of Madagascar, official website, reported on February 18th that tourists from China were detained by Madagascar police on suspicion of bringing chameleons and other prohibited items out of the country. At present, the matter is in the stage of judicial review, and there is no specific court date.

       This outdoor activity was jointly initiated by Wu and Ma, and set off from China on February 6th at the tropical rain forest on the east and west coasts of Madagascar. Most of the members who participated in the outdoor activities were children and parents who liked insects, animals and plants. According to media reports, the wild animals seized this time, including a chameleon, a lizard and fifteen centipedes, were all placed in plastic boxes covered with cotton wool. Lawyers said that those involved may face a fine of 40,000 euros.

one

       Malaysia has strict regulations on the exit of "endangered animals and plants"

       Let’s also briefly understand Madagascar’s strict regulations on the entry and exit of endangered animals and plants. Just now, we saw a lawyer say that if you leave the country with endangered animals and plants according to previous local laws, you may face a fine of 40,000 euros, equivalent to about 300,000 yuan. However, we also checked the entry-exit customs office at the airport in Tanana Lifu, Madagascar’s capital, and clearly posted the management requirements for carrying jewelry, herbs, endangered animals and plants, frozen meat, alcohol and other items. The maximum penalty is far more than the 40,000 euros mentioned by lawyers.

       According to Malaysian customs regulations, if you carry "endangered animals and plants", you need to apply for the import and export license allowed by the Convention on International Trade in Endangered Species of Wild Fauna and Flora, and you need to apply for an epidemic prevention certificate if you carry "live animals"; Once violations are found, those who transport endangered animals and plants without permission will be punished with 2 to 10 years’ imprisonment and a fine of up to 200 million Arial (equivalent to about 400,000 yuan). Although not all kinds of chameleons, lizards and centipedes are endangered animals, the corresponding criminal punishment of "transporting endangered animals and plants" is the heaviest compared with illegal transportation of drugs, weapons and illegal food in Malaysian customs regulations.

       Not by chance? The organizers involved are frequently exposed.

       What is the truth of this case, we have to wait for the Malaysian judicial review and court session to come to the bottom. However, some background about this "China tourists are suspected of bringing chameleons back to China privately" has also attracted great media attention. After the incident, some media found that this did not seem to be an accident. Because the so-called "organizers" Ma Moumou and Wu Mou, who went to Madagascar for a popular science parent-child tour, were previously exposed to abetting and luring children and parents to hunt protected wild animals and bring them into the country, not only "teaching children to catch bats with their bare hands", but also "teaching children to catch wild animals". At the same time, another "organizer" Wu Mou also flowed out on the Internet, and in Weibo, he exposed various "intimate photos" of Malaysian animals and plants such as chameleons during his trip to Malaysia, but the legality could not be confirmed; However, after the incident, Wu Mou, the organizer of the group, deleted a large number of Weibo words and pictures. In addition, as far as Ma’s identity is concerned, some media have revealed that he is an "expert who impersonates a member of the Science Education Alliance of the Chinese Academy of Sciences", but in fact he is an insect dealer who sells wild animals and plants, but this statement has not been verified. In this regard, on February 19, the official micro "Voice of the Chinese Academy of Sciences" of the Chinese Academy of Sciences also forwarded "Ma Moumou pretends to be Weibo, a so-called expert of Chinese Academy of Sciences.

one

       Expert Interpretation: Wild animals and plants should be "viewed from a distance"

       In recent years, popular science parent-child travel is very popular, but what should we pay attention to when we are in close contact with wild animals? Come and listen to the expert’s analysis.

       Experts said that ecotourism, as a new way of tourism, is deeply loved by parents and friends because it is close to nature and entertaining. However, wild animals often carry viruses themselves and their temperament is elusive. It is very dangerous to reach out and touch without isolation measures, not to mention catching them by hand or even bringing exotic species back to China. Experts say that in addition to violating the Convention on International Trade in Endangered Species of Wild Fauna and Flora, bringing exotic species back to China will also lead to species invasion, which will damage biodiversity protection and ecological environment.

       So how should we treat wild animals? Experts suggest that tourists should respect all life in nature and get to know them without disturbing their normal life.

       Zhang Na, an expert in animal and plant protection, said, "I think we should follow the principle of three noes when dealing with wild animals, that is, no trapping, no touching and no disturbing. We should know from an early age that wild animals belong to nature and are our friends, so we should respect them. We will observe them and understand them without disturbing their normal life, and then we hope that everyone can respect all life in nature. "